{
  "data": {
    "type": "predisposition_risk",
    "data": [
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MELPHALAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MELPHALAN",
        "rr": 111.45,
        "risk_count": 1512,
        "predisposition_and_risk": 187,
        "risk_duration": 29031718,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.THALIDOMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 102.62,
        "risk_count": 3839,
        "predisposition_and_risk": 440,
        "risk_duration": 28844379,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POMALIDOMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POMALIDOMIDE",
        "rr": 98.88,
        "risk_count": 1085,
        "predisposition_and_risk": 119,
        "risk_duration": 29045420,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARFILZOMIB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CARFILZOMIB",
        "rr": 98.26,
        "risk_count": 3323,
        "predisposition_and_risk": 364,
        "risk_duration": 28899161,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MELPHALAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MELPHALAN",
        "rr": 93.85,
        "risk_count": 2097,
        "predisposition_and_risk": 237,
        "risk_duration": 23433200,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LENALIDOMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LENALIDOMIDE",
        "rr": 91.81,
        "risk_count": 4535,
        "predisposition_and_risk": 466,
        "risk_duration": 28784713,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DARATUMUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DARATUMUMAB",
        "rr": 91.02,
        "risk_count": 375,
        "predisposition_and_risk": 41,
        "risk_duration": 23490489,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POMALIDOMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POMALIDOMIDE",
        "rr": 89.75,
        "risk_count": 668,
        "predisposition_and_risk": 72,
        "risk_duration": 23497314,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THALIDOMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 88.28,
        "risk_count": 4428,
        "predisposition_and_risk": 476,
        "risk_duration": 23173489,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARFILZOMIB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CARFILZOMIB",
        "rr": 76.31,
        "risk_count": 3943,
        "predisposition_and_risk": 365,
        "risk_duration": 23263016,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DARATUMUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DARATUMUMAB",
        "rr": 74.41,
        "risk_count": 570,
        "predisposition_and_risk": 47,
        "risk_duration": 29071543,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LENALIDOMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LENALIDOMIDE",
        "rr": 70.13,
        "risk_count": 6444,
        "predisposition_and_risk": 551,
        "risk_duration": 23144813,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BORTEZOMIB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BORTEZOMIB",
        "rr": 48.13,
        "risk_count": 10441,
        "predisposition_and_risk": 570,
        "risk_duration": 28402082,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLODRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLODRONIC ACID",
        "rr": 45.73,
        "risk_count": 4001,
        "predisposition_and_risk": 222,
        "risk_duration": 23258227,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BORTEZOMIB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BORTEZOMIB",
        "rr": 39.64,
        "risk_count": 11300,
        "predisposition_and_risk": 553,
        "risk_duration": 22858860,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VALACICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 32.69,
        "risk_count": 1371,
        "predisposition_and_risk": 54,
        "risk_duration": 23419110,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DAPSONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DAPSONE",
        "rr": 30.2,
        "risk_count": 1341,
        "predisposition_and_risk": 45,
        "risk_duration": 28991075,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CYCLOPHOSPHAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CYCLOPHOSPHAMIDE",
        "rr": 28.48,
        "risk_count": 4325,
        "predisposition_and_risk": 150,
        "risk_duration": 23175475,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LOPINAVIR_.2D_RITONAVIR_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LOPINAVIR - RITONAVIR CD",
        "rr": 26.89,
        "risk_count": 2629,
        "predisposition_and_risk": 86,
        "risk_duration": 23198481,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PAMIDRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PAMIDRONIC ACID",
        "rr": 24.48,
        "risk_count": 16560,
        "predisposition_and_risk": 511,
        "risk_duration": 22384118,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COMBIVIR_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "COMBIVIR CD",
        "rr": 24.35,
        "risk_count": 1963,
        "predisposition_and_risk": 58,
        "risk_duration": 23259605,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PAMIDRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PAMIDRONIC ACID",
        "rr": 18.78,
        "risk_count": 24555,
        "predisposition_and_risk": 550,
        "risk_duration": 27010488,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ZOLEDRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 16.74,
        "risk_count": 9681,
        "predisposition_and_risk": 199,
        "risk_duration": 22984969,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOPINAVIR_.2D_RITONAVIR_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LOPINAVIR - RITONAVIR CD",
        "rr": 16.55,
        "risk_count": 1190,
        "predisposition_and_risk": 22,
        "risk_duration": 28837944,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CYCLOPHOSPHAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CYCLOPHOSPHAMIDE",
        "rr": 16.05,
        "risk_count": 6613,
        "predisposition_and_risk": 120,
        "risk_duration": 28495262,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYCODONE_AND_ACETYLSALICYLIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYCODONE AND ACETYLSALICYLIC ACID",
        "rr": 15.27,
        "risk_count": 2115,
        "predisposition_and_risk": 36,
        "risk_duration": 28892051,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LAMIVUDINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LAMIVUDINE",
        "rr": 14.84,
        "risk_count": 17093,
        "predisposition_and_risk": 298,
        "risk_duration": 27431685,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FILGRASTIM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FILGRASTIM",
        "rr": 14.69,
        "risk_count": 13650,
        "predisposition_and_risk": 250,
        "risk_duration": 22637777,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IMMUNOGLOBULINS_IV_HUMAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IMMUNOGLOBULINS IV HUMAN",
        "rr": 13.75,
        "risk_count": 20656,
        "predisposition_and_risk": 334,
        "risk_duration": 27387969,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOLUTEGRAVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOLUTEGRAVIR",
        "rr": 13.19,
        "risk_count": 1022,
        "predisposition_and_risk": 15,
        "risk_duration": 28954223,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IMMUNOGLOBULINS_IV_HUMAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IMMUNOGLOBULINS IV HUMAN",
        "rr": 12.2,
        "risk_count": 19007,
        "predisposition_and_risk": 296,
        "risk_duration": 22102062,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIOTHYRONINE_SODIUM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LIOTHYRONINE SODIUM",
        "rr": 11.31,
        "risk_count": 1249,
        "predisposition_and_risk": 17,
        "risk_duration": 23449728,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VALACICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 11.13,
        "risk_count": 1613,
        "predisposition_and_risk": 20,
        "risk_duration": 28908975,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SULTIAME",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 10.71,
        "risk_count": 1092,
        "predisposition_and_risk": 13,
        "risk_duration": 28988658,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LIOTHYRONINE_SODIUM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LIOTHYRONINE SODIUM",
        "rr": 10.18,
        "risk_count": 3330,
        "predisposition_and_risk": 38,
        "risk_duration": 28744684,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EUCARBON_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EUCARBON CD",
        "rr": 10.02,
        "risk_count": 2772,
        "predisposition_and_risk": 31,
        "risk_duration": 28868021,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENTECAVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENTECAVIR",
        "rr": 9.75,
        "risk_count": 6787,
        "predisposition_and_risk": 75,
        "risk_duration": 28415907,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ERTAPENEM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ERTAPENEM",
        "rr": 9.33,
        "risk_count": 1158,
        "predisposition_and_risk": 12,
        "risk_duration": 29017863,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FILGRASTIM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FILGRASTIM",
        "rr": 8.93,
        "risk_count": 17586,
        "predisposition_and_risk": 183,
        "risk_duration": 27653357,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLODRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLODRONIC ACID",
        "rr": 8.63,
        "risk_count": 15861,
        "predisposition_and_risk": 158,
        "risk_duration": 27904265,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BETANECHOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BETANECHOL",
        "rr": 8.48,
        "risk_count": 3174,
        "predisposition_and_risk": 30,
        "risk_duration": 28909889,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LEVOFLOXACIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LEVOFLOXACIN",
        "rr": 8.15,
        "risk_count": 1730,
        "predisposition_and_risk": 17,
        "risk_duration": 23406873,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MORPHINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MORPHINE",
        "rr": 7.22,
        "risk_count": 22680,
        "predisposition_and_risk": 220,
        "risk_duration": 21009880,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LAMIVUDINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LAMIVUDINE",
        "rr": 7.21,
        "risk_count": 26396,
        "predisposition_and_risk": 257,
        "risk_duration": 20888401,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZOLEDRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 6.19,
        "risk_count": 21530,
        "predisposition_and_risk": 157,
        "risk_duration": 27353471,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TENOFOVIR_DISOPROXIL_AND_EMTRICITABINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 6.17,
        "risk_count": 3308,
        "predisposition_and_risk": 23,
        "risk_duration": 28606916,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BENDAMUSTINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BENDAMUSTINE",
        "rr": 6.06,
        "risk_count": 1927,
        "predisposition_and_risk": 13,
        "risk_duration": 28957954,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GRANISETRON",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GRANISETRON",
        "rr": 5.74,
        "risk_count": 17500,
        "predisposition_and_risk": 117,
        "risk_duration": 27679954,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CO.2DTRIMOXAZOLE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CO-TRIMOXAZOLE CD",
        "rr": 5.71,
        "risk_count": 57525,
        "predisposition_and_risk": 455,
        "risk_duration": 23276814,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GRANISETRON",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GRANISETRON",
        "rr": 5.68,
        "risk_count": 12186,
        "predisposition_and_risk": 86,
        "risk_duration": 22697571,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYCODONE.2C_AND_NALOXONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYCODONE, AND NALOXONE",
        "rr": 5.6,
        "risk_count": 52612,
        "predisposition_and_risk": 431,
        "risk_duration": 19290506,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RALTEGRAVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RALTEGRAVIR",
        "rr": 5.26,
        "risk_count": 2496,
        "predisposition_and_risk": 16,
        "risk_duration": 23157040,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CO.2DTRIMOXAZOLE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CO-TRIMOXAZOLE CD",
        "rr": 5.26,
        "risk_count": 55565,
        "predisposition_and_risk": 450,
        "risk_duration": 18325052,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PEGFILGRASTIM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PEGFILGRASTIM",
        "rr": 5.06,
        "risk_count": 11942,
        "predisposition_and_risk": 75,
        "risk_duration": 22730564,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RIFAMPICIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RIFAMPICIN",
        "rr": 4.83,
        "risk_count": 2964,
        "predisposition_and_risk": 16,
        "risk_duration": 28811923,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ONDANSETRON",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ONDANSETRON",
        "rr": 4.77,
        "risk_count": 18460,
        "predisposition_and_risk": 103,
        "risk_duration": 27536398,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYCODONE.2C_AND_NALOXONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYCODONE, AND NALOXONE",
        "rr": 4.76,
        "risk_count": 56584,
        "predisposition_and_risk": 352,
        "risk_duration": 24636992,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PALONOSETRON",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PALONOSETRON",
        "rr": 4.74,
        "risk_count": 6002,
        "predisposition_and_risk": 32,
        "risk_duration": 28660989,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OSELTAMIVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OSELTAMIVIR",
        "rr": 4.71,
        "risk_count": 2470,
        "predisposition_and_risk": 13,
        "risk_duration": 28833222,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZOLMITRIPTAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 4.57,
        "risk_count": 9438,
        "predisposition_and_risk": 50,
        "risk_duration": 27767239,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VORICONAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 4.54,
        "risk_count": 2178,
        "predisposition_and_risk": 11,
        "risk_duration": 28949498,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PERICIAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PERICIAZINE",
        "rr": 4.52,
        "risk_count": 4501,
        "predisposition_and_risk": 23,
        "risk_duration": 28518595,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INTERFERON_BETA.2D1A",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INTERFERON BETA-1A",
        "rr": 4.43,
        "risk_count": 4794,
        "predisposition_and_risk": 26,
        "risk_duration": 23042022,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACICLOVIR",
        "rr": 4.29,
        "risk_count": 59573,
        "predisposition_and_risk": 416,
        "risk_duration": 17347871,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCILESS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALCILESS CD",
        "rr": 4.29,
        "risk_count": 4575,
        "predisposition_and_risk": 22,
        "risk_duration": 28751991,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TAMOXIFEN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 4.06,
        "risk_count": 6453,
        "predisposition_and_risk": 32,
        "risk_duration": 23084112,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FENTANYL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FENTANYL",
        "rr": 4.02,
        "risk_count": 61878,
        "predisposition_and_risk": 411,
        "risk_duration": 17085974,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MORPHINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MORPHINE",
        "rr": 3.98,
        "risk_count": 25382,
        "predisposition_and_risk": 122,
        "risk_duration": 26662263,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TENOFOVIR_DISOPROXIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 3.96,
        "risk_count": 10105,
        "predisposition_and_risk": 50,
        "risk_duration": 22587131,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SUPERSHAKE_HIGH_PROTEIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 3.95,
        "risk_count": 3856,
        "predisposition_and_risk": 17,
        "risk_duration": 28874849,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRANEXAMIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 3.88,
        "risk_count": 6320,
        "predisposition_and_risk": 30,
        "risk_duration": 23082930,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUCONAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLUCONAZOLE",
        "rr": 3.79,
        "risk_count": 19141,
        "predisposition_and_risk": 94,
        "risk_duration": 21799527,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BROMOCRIPTINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BROMOCRIPTINE",
        "rr": 3.75,
        "risk_count": 6720,
        "predisposition_and_risk": 31,
        "risk_duration": 22952679,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FENTANYL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FENTANYL",
        "rr": 3.75,
        "risk_count": 79395,
        "predisposition_and_risk": 444,
        "risk_duration": 21621098,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MIDODRINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIDODRINE",
        "rr": 3.62,
        "risk_count": 8743,
        "predisposition_and_risk": 39,
        "risk_duration": 22897136,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCILESS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALCILESS CD",
        "rr": 3.6,
        "risk_count": 6129,
        "predisposition_and_risk": 27,
        "risk_duration": 23082797,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NIFEDIPINE.2DISDN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NIFEDIPINE-ISDN",
        "rr": 3.4,
        "risk_count": 3387,
        "predisposition_and_risk": 14,
        "risk_duration": 23200337,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.URALYT.2DU_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 3.38,
        "risk_count": 3415,
        "predisposition_and_risk": 14,
        "risk_duration": 23231089,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PEGFILGRASTIM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PEGFILGRASTIM",
        "rr": 3.32,
        "risk_count": 18048,
        "predisposition_and_risk": 70,
        "risk_duration": 27569160,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TENOFOVIR_DISOPROXIL_AND_EMTRICITABINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 3.32,
        "risk_count": 3906,
        "predisposition_and_risk": 16,
        "risk_duration": 22864658,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MERCAPTOPURINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MERCAPTOPURINE",
        "rr": 3.3,
        "risk_count": 9295,
        "predisposition_and_risk": 35,
        "risk_duration": 28228014,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LABETALOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LABETALOL",
        "rr": 3.2,
        "risk_count": 6401,
        "predisposition_and_risk": 25,
        "risk_duration": 23143001,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NEEDLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NEEDLE",
        "rr": 3.16,
        "risk_count": 3954,
        "predisposition_and_risk": 14,
        "risk_duration": 28770335,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYPODERMIC_NEEDLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYPODERMIC NEEDLE",
        "rr": 3.14,
        "risk_count": 3977,
        "predisposition_and_risk": 14,
        "risk_duration": 28766970,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OLMESARTAN_MEDOXOMIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OLMESARTAN MEDOXOMIL",
        "rr": 3.11,
        "risk_count": 3179,
        "predisposition_and_risk": 12,
        "risk_duration": 23270380,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SUREPRESS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 3.08,
        "risk_count": 3214,
        "predisposition_and_risk": 12,
        "risk_duration": 23295193,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VALGANCICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 3.07,
        "risk_count": 3485,
        "predisposition_and_risk": 12,
        "risk_duration": 28763294,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CIMETIDINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CIMETIDINE",
        "rr": 3,
        "risk_count": 12233,
        "predisposition_and_risk": 42,
        "risk_duration": 28117856,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ZINC_SULFATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.99,
        "risk_count": 10521,
        "predisposition_and_risk": 39,
        "risk_duration": 22789367,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYCOCIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYCOCIN CD",
        "rr": 2.96,
        "risk_count": 3327,
        "predisposition_and_risk": 11,
        "risk_duration": 28800870,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.STALEVO_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.9,
        "risk_count": 23381,
        "predisposition_and_risk": 86,
        "risk_duration": 22241115,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IRINOTECAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IRINOTECAN",
        "rr": 2.89,
        "risk_count": 8174,
        "predisposition_and_risk": 29,
        "risk_duration": 22948738,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.UMECLIDINIUM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.87,
        "risk_count": 9264,
        "predisposition_and_risk": 30,
        "risk_duration": 28519608,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NORTRIPTYLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NORTRIPTYLINE",
        "rr": 2.86,
        "risk_count": 18417,
        "predisposition_and_risk": 61,
        "risk_duration": 27798137,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIDODRINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIDODRINE",
        "rr": 2.82,
        "risk_count": 8774,
        "predisposition_and_risk": 28,
        "risk_duration": 28483483,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INTERFERON_BETA.2D1A",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INTERFERON BETA-1A",
        "rr": 2.79,
        "risk_count": 13427,
        "predisposition_and_risk": 44,
        "risk_duration": 27469838,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACICLOVIR",
        "rr": 2.76,
        "risk_count": 85823,
        "predisposition_and_risk": 412,
        "risk_duration": 18511086,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RITUXIMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RITUXIMAB",
        "rr": 2.75,
        "risk_count": 12812,
        "predisposition_and_risk": 44,
        "risk_duration": 22600602,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MODAFINIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MODAFINIL",
        "rr": 2.72,
        "risk_count": 3935,
        "predisposition_and_risk": 13,
        "risk_duration": 23241626,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ERYTHROPOIETIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ERYTHROPOIETIN",
        "rr": 2.69,
        "risk_count": 106023,
        "predisposition_and_risk": 469,
        "risk_duration": 19568521,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRANEXAMIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.66,
        "risk_count": 8355,
        "predisposition_and_risk": 26,
        "risk_duration": 27576362,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DIETHYLTOLUAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DIETHYLTOLUAMIDE",
        "rr": 2.65,
        "risk_count": 9736,
        "predisposition_and_risk": 32,
        "risk_duration": 22723442,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DEXAMETHASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXAMETHASONE",
        "rr": 2.64,
        "risk_count": 88815,
        "predisposition_and_risk": 438,
        "risk_duration": 15134176,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PALIPERIDONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PALIPERIDONE",
        "rr": 2.6,
        "risk_count": 5627,
        "predisposition_and_risk": 18,
        "risk_duration": 22975442,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CICLOSPORIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CICLOSPORIN",
        "rr": 2.59,
        "risk_count": 25038,
        "predisposition_and_risk": 79,
        "risk_duration": 26396819,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LID.2DCARE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LID-CARE CD",
        "rr": 2.59,
        "risk_count": 4126,
        "predisposition_and_risk": 13,
        "risk_duration": 23229560,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OPTRYL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OPTRYL CD",
        "rr": 2.54,
        "risk_count": 19498,
        "predisposition_and_risk": 64,
        "risk_duration": 21865665,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POVIDONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POVIDONE",
        "rr": 2.54,
        "risk_count": 17795,
        "predisposition_and_risk": 53,
        "risk_duration": 27477417,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.IMATINIB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IMATINIB",
        "rr": 2.5,
        "risk_count": 14007,
        "predisposition_and_risk": 44,
        "risk_duration": 22442711,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIZOLASTINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIZOLASTINE",
        "rr": 2.5,
        "risk_count": 17656,
        "predisposition_and_risk": 52,
        "risk_duration": 27325398,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROTHIAZINE.2FPROMETHAZINE_EXPECTORANT_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROTHIAZINE/PROMETHAZINE EXPECTORANT CD",
        "rr": 2.47,
        "risk_count": 16066,
        "predisposition_and_risk": 51,
        "risk_duration": 21967496,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NYSTATIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NYSTATIN",
        "rr": 2.46,
        "risk_count": 25440,
        "predisposition_and_risk": 75,
        "risk_duration": 26872264,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DARBEPOETIN_ALFA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DARBEPOETIN ALFA",
        "rr": 2.46,
        "risk_count": 91615,
        "predisposition_and_risk": 333,
        "risk_duration": 21844976,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RETINOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RETINOL",
        "rr": 2.45,
        "risk_count": 7609,
        "predisposition_and_risk": 21,
        "risk_duration": 28576314,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2DTRAVOPROST_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.45,
        "risk_count": 14146,
        "predisposition_and_risk": 43,
        "risk_duration": 22728515,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VITA.2DCAL.2BD.2BMINERALS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.44,
        "risk_count": 30197,
        "predisposition_and_risk": 97,
        "risk_duration": 21398114,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLARITHROMYCIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLARITHROMYCIN",
        "rr": 2.42,
        "risk_count": 26079,
        "predisposition_and_risk": 86,
        "risk_duration": 20683808,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OMALIZUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OMALIZUMAB",
        "rr": 2.41,
        "risk_count": 14045,
        "predisposition_and_risk": 39,
        "risk_duration": 27921460,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOCETAXEL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOCETAXEL",
        "rr": 2.41,
        "risk_count": 9112,
        "predisposition_and_risk": 25,
        "risk_duration": 28344119,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GOSERELIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GOSERELIN",
        "rr": 2.41,
        "risk_count": 12122,
        "predisposition_and_risk": 36,
        "risk_duration": 22918906,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NEPHROCARE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NEPHROCARE CD",
        "rr": 2.41,
        "risk_count": 20030,
        "predisposition_and_risk": 61,
        "risk_duration": 22376575,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INFLIXIMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INFLIXIMAB",
        "rr": 2.4,
        "risk_count": 10527,
        "predisposition_and_risk": 29,
        "risk_duration": 28076933,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAGNESIUM_SULFATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAGNESIUM SULFATE",
        "rr": 2.36,
        "risk_count": 4863,
        "predisposition_and_risk": 14,
        "risk_duration": 23097387,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SODIUM_CL_FOR_IRRIGATION",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.32,
        "risk_count": 10191,
        "predisposition_and_risk": 27,
        "risk_duration": 28258797,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SILDENAFIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.3,
        "risk_count": 19546,
        "predisposition_and_risk": 52,
        "risk_duration": 27849844,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TINIDAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.29,
        "risk_count": 6538,
        "predisposition_and_risk": 17,
        "risk_duration": 28349114,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALAMINE_LOTION_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALAMINE LOTION CD",
        "rr": 2.29,
        "risk_count": 20353,
        "predisposition_and_risk": 55,
        "risk_duration": 27279735,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CROMOGLICIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CROMOGLICIC ACID",
        "rr": 2.29,
        "risk_count": 25653,
        "predisposition_and_risk": 71,
        "risk_duration": 26683350,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMISULPRIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AMISULPRIDE",
        "rr": 2.26,
        "risk_count": 12485,
        "predisposition_and_risk": 33,
        "risk_duration": 27556081,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AMISULPRIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AMISULPRIDE",
        "rr": 2.25,
        "risk_count": 9168,
        "predisposition_and_risk": 26,
        "risk_duration": 22404027,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENOXYMETHYLPENICILLIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PHENOXYMETHYLPENICILLIN",
        "rr": 2.22,
        "risk_count": 41222,
        "predisposition_and_risk": 141,
        "risk_duration": 18293588,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIUM_FOLINATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALCIUM FOLINATE",
        "rr": 2.22,
        "risk_count": 6413,
        "predisposition_and_risk": 16,
        "risk_duration": 28608068,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MEGESTROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MEGESTROL",
        "rr": 2.22,
        "risk_count": 5571,
        "predisposition_and_risk": 15,
        "risk_duration": 23219111,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIXISENATIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LIXISENATIDE",
        "rr": 2.21,
        "risk_count": 11638,
        "predisposition_and_risk": 32,
        "risk_duration": 22683344,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CAPECITABINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CAPECITABINE",
        "rr": 2.2,
        "risk_count": 16414,
        "predisposition_and_risk": 42,
        "risk_duration": 27742936,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NYSTATIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NYSTATIN",
        "rr": 2.19,
        "risk_count": 18929,
        "predisposition_and_risk": 53,
        "risk_duration": 22033159,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ROPINIROLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ROPINIROLE",
        "rr": 2.19,
        "risk_count": 27470,
        "predisposition_and_risk": 78,
        "risk_duration": 21738687,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TROMANTADINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.19,
        "risk_count": 4489,
        "predisposition_and_risk": 12,
        "risk_duration": 23100725,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2DTRAVOPROST_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.18,
        "risk_count": 16493,
        "predisposition_and_risk": 41,
        "risk_duration": 28222262,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DUO.2DSCABIL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DUO-SCABIL CD",
        "rr": 2.15,
        "risk_count": 4558,
        "predisposition_and_risk": 11,
        "risk_duration": 28687498,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FULVESTRANT",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FULVESTRANT",
        "rr": 2.13,
        "risk_count": 9144,
        "predisposition_and_risk": 22,
        "risk_duration": 28467564,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MIDAZOLAM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIDAZOLAM",
        "rr": 2.12,
        "risk_count": 4629,
        "predisposition_and_risk": 12,
        "risk_duration": 23122915,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PNEUMOCOCCUS.2C_PURIFIED_POLYSACHARIDES_ANTIGEN_CONJUGATED",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PNEUMOCOCCUS, PURIFIED POLYSACHARIDES ANTIGEN CONJUGATED",
        "rr": 2.1,
        "risk_count": 23295,
        "predisposition_and_risk": 63,
        "risk_duration": 21911126,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VINORELBINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.1,
        "risk_count": 12057,
        "predisposition_and_risk": 29,
        "risk_duration": 28066414,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAGNESIUM_OXIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAGNESIUM OXIDE",
        "rr": 2.08,
        "risk_count": 46248,
        "predisposition_and_risk": 133,
        "risk_duration": 20424260,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.STALEVO_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 2.07,
        "risk_count": 18068,
        "predisposition_and_risk": 43,
        "risk_duration": 27999610,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BENZIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BENZIN",
        "rr": 2.05,
        "risk_count": 5207,
        "predisposition_and_risk": 12,
        "risk_duration": 28718501,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUCONAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLUCONAZOLE",
        "rr": 2.05,
        "risk_count": 34605,
        "predisposition_and_risk": 93,
        "risk_duration": 24564804,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MIDRO.2DTEA_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIDRO-TEA CD",
        "rr": 2.05,
        "risk_count": 9100,
        "predisposition_and_risk": 23,
        "risk_duration": 22852196,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYMETAZOLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYMETAZOLINE",
        "rr": 2.04,
        "risk_count": 71324,
        "predisposition_and_risk": 228,
        "risk_duration": 20588730,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXAMETHASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXAMETHASONE",
        "rr": 2.03,
        "risk_count": 107250,
        "predisposition_and_risk": 390,
        "risk_duration": 18004975,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POLYVINYL_ALCOHOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POLYVINYL ALCOHOL",
        "rr": 2,
        "risk_count": 8143,
        "predisposition_and_risk": 20,
        "risk_duration": 22933213,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SEVELAMER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.99,
        "risk_count": 46304,
        "predisposition_and_risk": 116,
        "risk_duration": 25598720,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NEPHROCARE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NEPHROCARE CD",
        "rr": 1.98,
        "risk_count": 18484,
        "predisposition_and_risk": 42,
        "risk_duration": 28125826,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SODIUM_CHLORIDE.2C_HYPERTONIC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.97,
        "risk_count": 8564,
        "predisposition_and_risk": 19,
        "risk_duration": 28597439,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RITUXIMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RITUXIMAB",
        "rr": 1.96,
        "risk_count": 14623,
        "predisposition_and_risk": 33,
        "risk_duration": 27981176,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.URSODEOXYCHOLIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.96,
        "risk_count": 29718,
        "predisposition_and_risk": 79,
        "risk_duration": 20828021,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VITAMIN_B_COMPLEX.2BVIT.2EC_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.96,
        "risk_count": 9458,
        "predisposition_and_risk": 23,
        "risk_duration": 22747822,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUOROURACIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLUOROURACIL",
        "rr": 1.95,
        "risk_count": 17683,
        "predisposition_and_risk": 40,
        "risk_duration": 27734601,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SULFASALAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.94,
        "risk_count": 17631,
        "predisposition_and_risk": 44,
        "risk_duration": 21944120,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CEFTRIAXONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CEFTRIAXONE",
        "rr": 1.93,
        "risk_count": 13178,
        "predisposition_and_risk": 32,
        "risk_duration": 22458601,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.REBOXETINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "REBOXETINE",
        "rr": 1.92,
        "risk_count": 17004,
        "predisposition_and_risk": 42,
        "risk_duration": 21925219,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SODIUM_BICARBONATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.91,
        "risk_count": 14102,
        "predisposition_and_risk": 31,
        "risk_duration": 27987897,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCIUM_GLUBIONATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALCIUM GLUBIONATE",
        "rr": 1.91,
        "risk_count": 17734,
        "predisposition_and_risk": 43,
        "risk_duration": 22170900,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LOTEPREDNOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LOTEPREDNOL",
        "rr": 1.9,
        "risk_count": 7296,
        "predisposition_and_risk": 17,
        "risk_duration": 22998617,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TOCILIZUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.89,
        "risk_count": 10643,
        "predisposition_and_risk": 23,
        "risk_duration": 28200630,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VITAMIN_B_COMPLEX.2BVIT.2EC_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.89,
        "risk_count": 16373,
        "predisposition_and_risk": 36,
        "risk_duration": 27711380,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EXAMINATION_GLOVES",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EXAMINATION GLOVES",
        "rr": 1.89,
        "risk_count": 15091,
        "predisposition_and_risk": 36,
        "risk_duration": 22393455,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PRAMIPEXOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PRAMIPEXOLE",
        "rr": 1.88,
        "risk_count": 13743,
        "predisposition_and_risk": 32,
        "risk_duration": 22758574,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ONDANSETRON",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ONDANSETRON",
        "rr": 1.87,
        "risk_count": 12020,
        "predisposition_and_risk": 28,
        "risk_duration": 22671611,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CETRIMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CETRIMIDE",
        "rr": 1.87,
        "risk_count": 8034,
        "predisposition_and_risk": 17,
        "risk_duration": 28450352,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CICLODERM.2DC_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CICLODERM-C CD",
        "rr": 1.86,
        "risk_count": 13616,
        "predisposition_and_risk": 32,
        "risk_duration": 22287951,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.APREPITANT",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "APREPITANT",
        "rr": 1.85,
        "risk_count": 22693,
        "predisposition_and_risk": 50,
        "risk_duration": 27092121,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MOVIPREP_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MOVIPREP CD",
        "rr": 1.85,
        "risk_count": 6173,
        "predisposition_and_risk": 14,
        "risk_duration": 23049999,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROGYM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROGYM CD",
        "rr": 1.84,
        "risk_count": 7099,
        "predisposition_and_risk": 16,
        "risk_duration": 23044173,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DAKTACORT_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DAKTACORT CD",
        "rr": 1.83,
        "risk_count": 30898,
        "predisposition_and_risk": 70,
        "risk_duration": 26044194,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LID.2DCARE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LID-CARE CD",
        "rr": 1.83,
        "risk_count": 6744,
        "predisposition_and_risk": 14,
        "risk_duration": 28395498,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PIOGLITAZONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PIOGLITAZONE",
        "rr": 1.82,
        "risk_count": 10593,
        "predisposition_and_risk": 22,
        "risk_duration": 28233926,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NIFEDIPINE.2DLIDOCAINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NIFEDIPINE-LIDOCAINE",
        "rr": 1.81,
        "risk_count": 9692,
        "predisposition_and_risk": 22,
        "risk_duration": 22544269,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POTASSIUM_CHLORIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POTASSIUM CHLORIDE",
        "rr": 1.81,
        "risk_count": 78907,
        "predisposition_and_risk": 204,
        "risk_duration": 22604332,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POLYETHYLENE_GLYCOL_400.2DPROPYLENE_GLYCOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POLYETHYLENE GLYCOL 400-PROPYLENE GLYCOL CD",
        "rr": 1.8,
        "risk_count": 11217,
        "predisposition_and_risk": 23,
        "risk_duration": 28335434,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUOROURACIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLUOROURACIL",
        "rr": 1.8,
        "risk_count": 20104,
        "predisposition_and_risk": 46,
        "risk_duration": 22150127,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLEXITOL_HEEL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLEXITOL HEEL",
        "rr": 1.79,
        "risk_count": 15507,
        "predisposition_and_risk": 35,
        "risk_duration": 22322541,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROXYCARBAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROXYCARBAMIDE",
        "rr": 1.79,
        "risk_count": 22926,
        "predisposition_and_risk": 53,
        "risk_duration": 21832380,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAGNESIUM_CITRATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAGNESIUM CITRATE",
        "rr": 1.79,
        "risk_count": 65095,
        "predisposition_and_risk": 181,
        "risk_duration": 18115556,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYCODONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYCODONE",
        "rr": 1.78,
        "risk_count": 105962,
        "predisposition_and_risk": 350,
        "risk_duration": 17324911,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PRASUGREL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PRASUGREL",
        "rr": 1.78,
        "risk_count": 14633,
        "predisposition_and_risk": 30,
        "risk_duration": 27914376,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BENZATHINE_BENZYLPENICILLIN.2DLIDOCANIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BENZATHINE BENZYLPENICILLIN-LIDOCANIN CD",
        "rr": 1.77,
        "risk_count": 5114,
        "predisposition_and_risk": 11,
        "risk_duration": 23178360,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TETRACYCLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.76,
        "risk_count": 6508,
        "predisposition_and_risk": 13,
        "risk_duration": 28425883,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DESMOPRESSIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DESMOPRESSIN",
        "rr": 1.76,
        "risk_count": 15595,
        "predisposition_and_risk": 32,
        "risk_duration": 27635857,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENSURE_PLUS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENSURE PLUS CD",
        "rr": 1.76,
        "risk_count": 68902,
        "predisposition_and_risk": 192,
        "risk_duration": 17843045,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRASTUZUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.75,
        "risk_count": 25076,
        "predisposition_and_risk": 53,
        "risk_duration": 26722226,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BETAXOLOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BETAXOLOL",
        "rr": 1.75,
        "risk_count": 16447,
        "predisposition_and_risk": 33,
        "risk_duration": 28163096,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLECAINIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLECAINIDE",
        "rr": 1.75,
        "risk_count": 37536,
        "predisposition_and_risk": 89,
        "risk_duration": 20812180,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXALIPLATIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXALIPLATIN",
        "rr": 1.74,
        "risk_count": 9312,
        "predisposition_and_risk": 20,
        "risk_duration": 22901065,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INHALER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INHALER",
        "rr": 1.74,
        "risk_count": 6093,
        "predisposition_and_risk": 13,
        "risk_duration": 23057814,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROTHIAZINE.2FPROMETHAZINE_EXPECTORANT_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROTHIAZINE/PROMETHAZINE EXPECTORANT CD",
        "rr": 1.73,
        "risk_count": 25600,
        "predisposition_and_risk": 54,
        "risk_duration": 26469862,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRINZOLAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BRINZOLAMIDE",
        "rr": 1.73,
        "risk_count": 32732,
        "predisposition_and_risk": 74,
        "risk_duration": 21539910,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FORMOTEROL_AND_BECLOMETASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FORMOTEROL AND BECLOMETASONE",
        "rr": 1.73,
        "risk_count": 10688,
        "predisposition_and_risk": 21,
        "risk_duration": 28357414,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENYPHRINE.2DAZOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PHENYPHRINE-AZOL CD",
        "rr": 1.72,
        "risk_count": 5694,
        "predisposition_and_risk": 12,
        "risk_duration": 22981842,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TERBUTALINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.72,
        "risk_count": 49928,
        "predisposition_and_risk": 127,
        "risk_duration": 19093678,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GAVISCON_ADVANCE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GAVISCON ADVANCE CD",
        "rr": 1.72,
        "risk_count": 8947,
        "predisposition_and_risk": 19,
        "risk_duration": 22894588,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SELF_CATHETER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.71,
        "risk_count": 13950,
        "predisposition_and_risk": 30,
        "risk_duration": 22433284,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TROLAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.71,
        "risk_count": 19573,
        "predisposition_and_risk": 43,
        "risk_duration": 21917288,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BEVACIZUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BEVACIZUMAB",
        "rr": 1.71,
        "risk_count": 9501,
        "predisposition_and_risk": 20,
        "risk_duration": 22883587,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CERUMOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CERUMOL CD",
        "rr": 1.71,
        "risk_count": 12480,
        "predisposition_and_risk": 27,
        "risk_duration": 22366089,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHOTREXATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHOTREXATE",
        "rr": 1.71,
        "risk_count": 72991,
        "predisposition_and_risk": 190,
        "risk_duration": 21189152,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEBHYDROLIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MEBHYDROLIN",
        "rr": 1.7,
        "risk_count": 7777,
        "predisposition_and_risk": 15,
        "risk_duration": 28326613,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IRINOTECAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IRINOTECAN",
        "rr": 1.69,
        "risk_count": 8381,
        "predisposition_and_risk": 16,
        "risk_duration": 28441345,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MILNACIPRAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MILNACIPRAN",
        "rr": 1.69,
        "risk_count": 10396,
        "predisposition_and_risk": 22,
        "risk_duration": 22528871,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASCORBIC_ACID_AND_CALCIUM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASCORBIC ACID AND CALCIUM CD",
        "rr": 1.68,
        "risk_count": 11504,
        "predisposition_and_risk": 24,
        "risk_duration": 22691702,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RANIBIZUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RANIBIZUMAB",
        "rr": 1.68,
        "risk_count": 5869,
        "predisposition_and_risk": 12,
        "risk_duration": 23177873,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SILVER_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.68,
        "risk_count": 13750,
        "predisposition_and_risk": 29,
        "risk_duration": 22486558,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TESTOSTERONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.68,
        "risk_count": 67637,
        "predisposition_and_risk": 187,
        "risk_duration": 17118692,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AZATHIOPRINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AZATHIOPRINE",
        "rr": 1.68,
        "risk_count": 42426,
        "predisposition_and_risk": 93,
        "risk_duration": 24697286,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BORIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BORIC ACID",
        "rr": 1.68,
        "risk_count": 9933,
        "predisposition_and_risk": 19,
        "risk_duration": 28273802,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MACROGOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MACROGOL",
        "rr": 1.68,
        "risk_count": 56224,
        "predisposition_and_risk": 138,
        "risk_duration": 19324239,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NIFEDIPINE.2DLIDOCAINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NIFEDIPINE-LIDOCAINE",
        "rr": 1.67,
        "risk_count": 11459,
        "predisposition_and_risk": 22,
        "risk_duration": 27990285,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXALIPLATIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXALIPLATIN",
        "rr": 1.67,
        "risk_count": 8445,
        "predisposition_and_risk": 16,
        "risk_duration": 28444441,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DENOSUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DENOSUMAB",
        "rr": 1.67,
        "risk_count": 18787,
        "predisposition_and_risk": 36,
        "risk_duration": 28129948,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2DBRIMONIDINE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.66,
        "risk_count": 22161,
        "predisposition_and_risk": 43,
        "risk_duration": 27598200,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TROMANTADINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.65,
        "risk_count": 10049,
        "predisposition_and_risk": 19,
        "risk_duration": 28070976,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DEXEFRIN.2FDETHAPHRINE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXEFRIN/DETHAPHRINE CD",
        "rr": 1.64,
        "risk_count": 15772,
        "predisposition_and_risk": 33,
        "risk_duration": 22095180,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOCETAXEL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOCETAXEL",
        "rr": 1.63,
        "risk_count": 5558,
        "predisposition_and_risk": 11,
        "risk_duration": 23189241,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RAFATHRICIN_WITH_BENZOCAINE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RAFATHRICIN WITH BENZOCAINE CD",
        "rr": 1.62,
        "risk_count": 25135,
        "predisposition_and_risk": 55,
        "risk_duration": 20927441,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DESIPRAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DESIPRAMINE",
        "rr": 1.62,
        "risk_count": 7609,
        "predisposition_and_risk": 14,
        "risk_duration": 28397348,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENOXAPARIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENOXAPARIN",
        "rr": 1.62,
        "risk_count": 114314,
        "predisposition_and_risk": 331,
        "risk_duration": 18028603,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROQUINONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROQUINONE",
        "rr": 1.62,
        "risk_count": 9634,
        "predisposition_and_risk": 18,
        "risk_duration": 27894623,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROXYCHLOROQUINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROXYCHLOROQUINE",
        "rr": 1.62,
        "risk_count": 67617,
        "predisposition_and_risk": 164,
        "risk_duration": 21552065,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LANTHANUM_CARBONATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LANTHANUM CARBONATE",
        "rr": 1.62,
        "risk_count": 25784,
        "predisposition_and_risk": 49,
        "risk_duration": 27409174,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MICROLET_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MICROLET CD",
        "rr": 1.62,
        "risk_count": 53827,
        "predisposition_and_risk": 115,
        "risk_duration": 24394808,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.APIXABAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "APIXABAN",
        "rr": 1.61,
        "risk_count": 68696,
        "predisposition_and_risk": 139,
        "risk_duration": 25616345,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SEVELAMER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.61,
        "risk_count": 50174,
        "predisposition_and_risk": 120,
        "risk_duration": 18966038,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DONEPEZIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DONEPEZIL",
        "rr": 1.61,
        "risk_count": 26376,
        "predisposition_and_risk": 49,
        "risk_duration": 27865189,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POTASSIUM_CHLORIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POTASSIUM CHLORIDE",
        "rr": 1.6,
        "risk_count": 79139,
        "predisposition_and_risk": 205,
        "risk_duration": 17408795,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ERYTHROPOIETIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ERYTHROPOIETIN",
        "rr": 1.6,
        "risk_count": 98395,
        "predisposition_and_risk": 334,
        "risk_duration": 13260757,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IRON_INJECTION_IV",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IRON INJECTION IV",
        "rr": 1.6,
        "risk_count": 95698,
        "predisposition_and_risk": 239,
        "risk_duration": 20640888,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ABDOMINAL_BINDER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ABDOMINAL BINDER",
        "rr": 1.59,
        "risk_count": 7672,
        "predisposition_and_risk": 15,
        "risk_duration": 22922464,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THERMOMETER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.59,
        "risk_count": 35407,
        "predisposition_and_risk": 79,
        "risk_duration": 20050702,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.XYLOMETAZOLINE.2DIPRATROPIUM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.59,
        "risk_count": 13515,
        "predisposition_and_risk": 25,
        "risk_duration": 27778405,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLYCOPYRRONIUM_BROMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLYCOPYRRONIUM BROMIDE",
        "rr": 1.59,
        "risk_count": 6181,
        "predisposition_and_risk": 11,
        "risk_duration": 28731410,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INFLIXIMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INFLIXIMAB",
        "rr": 1.59,
        "risk_count": 6623,
        "predisposition_and_risk": 13,
        "risk_duration": 22823137,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THYME_LIQUID_EXTRACT",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.58,
        "risk_count": 11068,
        "predisposition_and_risk": 22,
        "risk_duration": 22423713,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLARITHROMYCIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLARITHROMYCIN",
        "rr": 1.58,
        "risk_count": 36677,
        "predisposition_and_risk": 76,
        "risk_duration": 24615056,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LUBRICANS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LUBRICANS CD",
        "rr": 1.58,
        "risk_count": 8942,
        "predisposition_and_risk": 16,
        "risk_duration": 28410660,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BUTENAFINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BUTENAFINE",
        "rr": 1.57,
        "risk_count": 15532,
        "predisposition_and_risk": 31,
        "risk_duration": 22185739,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DARBEPOETIN_ALFA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DARBEPOETIN ALFA",
        "rr": 1.57,
        "risk_count": 86843,
        "predisposition_and_risk": 253,
        "risk_duration": 15246110,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EUCALYPTUS_OIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EUCALYPTUS OIL",
        "rr": 1.57,
        "risk_count": 9240,
        "predisposition_and_risk": 18,
        "risk_duration": 22780385,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DORZOLAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DORZOLAMIDE",
        "rr": 1.56,
        "risk_count": 39707,
        "predisposition_and_risk": 75,
        "risk_duration": 26554256,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAPROTILINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAPROTILINE",
        "rr": 1.56,
        "risk_count": 8850,
        "predisposition_and_risk": 17,
        "risk_duration": 22858134,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIGRALEVE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIGRALEVE CD",
        "rr": 1.56,
        "risk_count": 13610,
        "predisposition_and_risk": 25,
        "risk_duration": 27293291,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VILANTEROL_AND_FLUTICASONE_FUROATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.55,
        "risk_count": 50569,
        "predisposition_and_risk": 100,
        "risk_duration": 25248610,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AVENE.2FULTRASOL.2FSKIN_GAURD_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AVENE/ULTRASOL/SKIN GAURD CD",
        "rr": 1.55,
        "risk_count": 26354,
        "predisposition_and_risk": 55,
        "risk_duration": 20985469,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CHAMOMILE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CHAMOMILE",
        "rr": 1.55,
        "risk_count": 10150,
        "predisposition_and_risk": 18,
        "risk_duration": 28143560,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ISPAGHULA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ISPAGHULA",
        "rr": 1.55,
        "risk_count": 26415,
        "predisposition_and_risk": 54,
        "risk_duration": 21448692,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACITRETIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACITRETIN",
        "rr": 1.54,
        "risk_count": 14506,
        "predisposition_and_risk": 26,
        "risk_duration": 27663338,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRONCHOLATE_FORTE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BRONCHOLATE FORTE CD",
        "rr": 1.54,
        "risk_count": 25925,
        "predisposition_and_risk": 53,
        "risk_duration": 21194048,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DELMOPINOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DELMOPINOL",
        "rr": 1.54,
        "risk_count": 5841,
        "predisposition_and_risk": 11,
        "risk_duration": 23095297,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GABAPENTIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GABAPENTIN",
        "rr": 1.54,
        "risk_count": 59121,
        "predisposition_and_risk": 139,
        "risk_duration": 18493721,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_DEGLUDEC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULIN DEGLUDEC",
        "rr": 1.54,
        "risk_count": 26284,
        "predisposition_and_risk": 53,
        "risk_duration": 21494328,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ISOCONAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ISOCONAZOLE",
        "rr": 1.54,
        "risk_count": 10230,
        "predisposition_and_risk": 18,
        "risk_duration": 28248272,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAGNESIUM_HYDROXIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAGNESIUM HYDROXIDE",
        "rr": 1.54,
        "risk_count": 39708,
        "predisposition_and_risk": 74,
        "risk_duration": 26567965,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAGNESIUM_SULFATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAGNESIUM SULFATE",
        "rr": 1.54,
        "risk_count": 7445,
        "predisposition_and_risk": 13,
        "risk_duration": 28408131,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SOTALOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.53,
        "risk_count": 32949,
        "predisposition_and_risk": 61,
        "risk_duration": 26648288,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TUSSOPHEDRIN_NEW_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.53,
        "risk_count": 20170,
        "predisposition_and_risk": 37,
        "risk_duration": 26814959,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CAPECITABINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CAPECITABINE",
        "rr": 1.53,
        "risk_count": 8010,
        "predisposition_and_risk": 15,
        "risk_duration": 22999824,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TAMSULOSIN_AND_DUTASTERIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.52,
        "risk_count": 105958,
        "predisposition_and_risk": 258,
        "risk_duration": 17623779,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.JUNGBORN_TEA_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "JUNGBORN TEA CD",
        "rr": 1.52,
        "risk_count": 12086,
        "predisposition_and_risk": 23,
        "risk_duration": 22582755,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LABETALOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LABETALOL",
        "rr": 1.52,
        "risk_count": 8170,
        "predisposition_and_risk": 14,
        "risk_duration": 28592536,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MERIDOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MERIDOL CD",
        "rr": 1.52,
        "risk_count": 41533,
        "predisposition_and_risk": 90,
        "risk_duration": 19801107,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SODIUM_CHLORIDE.2C_HYPERTONIC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.51,
        "risk_count": 7032,
        "predisposition_and_risk": 13,
        "risk_duration": 23117174,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BENZATHINE_BENZYLPENICILLIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BENZATHINE BENZYLPENICILLIN",
        "rr": 1.51,
        "risk_count": 36763,
        "predisposition_and_risk": 69,
        "risk_duration": 25935670,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BORIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BORIC ACID",
        "rr": 1.51,
        "risk_count": 8579,
        "predisposition_and_risk": 16,
        "risk_duration": 22776001,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MESALAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MESALAZINE",
        "rr": 1.51,
        "risk_count": 55398,
        "predisposition_and_risk": 131,
        "risk_duration": 18025544,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALKASOLVE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ALKASOLVE CD",
        "rr": 1.5,
        "risk_count": 13164,
        "predisposition_and_risk": 25,
        "risk_duration": 22350145,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TOLTERODINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.5,
        "risk_count": 58227,
        "predisposition_and_risk": 125,
        "risk_duration": 19759678,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ITRACONAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ITRACONAZOLE",
        "rr": 1.5,
        "risk_count": 9052,
        "predisposition_and_risk": 17,
        "risk_duration": 22549834,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PILOCARPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PILOCARPINE",
        "rr": 1.49,
        "risk_count": 26782,
        "predisposition_and_risk": 47,
        "risk_duration": 27305662,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2DBRIMONIDINE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.49,
        "risk_count": 20666,
        "predisposition_and_risk": 39,
        "risk_duration": 22245326,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.URSODEOXYCHOLIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.49,
        "risk_count": 62672,
        "predisposition_and_risk": 127,
        "risk_duration": 23624961,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ATORVASTATIN_AND_EZETIMIBE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ATORVASTATIN AND EZETIMIBE",
        "rr": 1.49,
        "risk_count": 12829,
        "predisposition_and_risk": 22,
        "risk_duration": 28052467,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENOXAPARIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENOXAPARIN",
        "rr": 1.49,
        "risk_count": 97008,
        "predisposition_and_risk": 289,
        "risk_duration": 14130060,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MOVIPREP_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MOVIPREP CD",
        "rr": 1.49,
        "risk_count": 7124,
        "predisposition_and_risk": 12,
        "risk_duration": 28537460,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYCODONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYCODONE",
        "rr": 1.48,
        "risk_count": 84356,
        "predisposition_and_risk": 301,
        "risk_duration": 11671767,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLECAINIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLECAINIDE",
        "rr": 1.48,
        "risk_count": 61988,
        "predisposition_and_risk": 119,
        "risk_duration": 24763885,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ICHTHAMOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ICHTHAMOL",
        "rr": 1.48,
        "risk_count": 36343,
        "predisposition_and_risk": 69,
        "risk_duration": 25140376,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID.2DPROPOLIS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASCORBIC ACID-PROPOLIS CD",
        "rr": 1.47,
        "risk_count": 15165,
        "predisposition_and_risk": 26,
        "risk_duration": 27699028,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROGYM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROGYM CD",
        "rr": 1.47,
        "risk_count": 6654,
        "predisposition_and_risk": 11,
        "risk_duration": 28660099,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.THIAMINE_.28VIT.2E_B1.29",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.47,
        "risk_count": 11364,
        "predisposition_and_risk": 19,
        "risk_duration": 28283426,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TICAGRELOR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.47,
        "risk_count": 33424,
        "predisposition_and_risk": 67,
        "risk_duration": 20653749,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRICLOSAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.47,
        "risk_count": 23074,
        "predisposition_and_risk": 45,
        "risk_duration": 21297850,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ERYTHROMYCIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ERYTHROMYCIN",
        "rr": 1.47,
        "risk_count": 10226,
        "predisposition_and_risk": 19,
        "risk_duration": 22386324,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FINGER_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FINGER DRESSING",
        "rr": 1.47,
        "risk_count": 26176,
        "predisposition_and_risk": 51,
        "risk_duration": 21311979,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYALURONIC_ACID.2DLACTIC_ACID.2DUREA_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYALURONIC ACID-LACTIC ACID-UREA CD",
        "rr": 1.47,
        "risk_count": 23051,
        "predisposition_and_risk": 44,
        "risk_duration": 21739882,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INDACATEROL_AND_GLYCOPYRRONIUM_BROMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INDACATEROL AND GLYCOPYRRONIUM BROMIDE",
        "rr": 1.47,
        "risk_count": 9614,
        "predisposition_and_risk": 16,
        "risk_duration": 28535145,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYCODONE_AND_PARACETAMOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYCODONE AND PARACETAMOL",
        "rr": 1.46,
        "risk_count": 76414,
        "predisposition_and_risk": 221,
        "risk_duration": 14293518,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENOXYBENZAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PHENOXYBENZAMINE",
        "rr": 1.45,
        "risk_count": 27877,
        "predisposition_and_risk": 52,
        "risk_duration": 21921643,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POLYSTYRENE_SULFONATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POLYSTYRENE SULFONATE",
        "rr": 1.45,
        "risk_count": 49740,
        "predisposition_and_risk": 91,
        "risk_duration": 25586439,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BECLOMETHASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BECLOMETHASONE",
        "rr": 1.45,
        "risk_count": 14959,
        "predisposition_and_risk": 25,
        "risk_duration": 27864627,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BUPRENORPHINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BUPRENORPHINE",
        "rr": 1.45,
        "risk_count": 44556,
        "predisposition_and_risk": 80,
        "risk_duration": 25970253,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALAMINE_LOTION_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALAMINE LOTION CD",
        "rr": 1.45,
        "risk_count": 12126,
        "predisposition_and_risk": 22,
        "risk_duration": 22553470,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHARCOAL_MEDICINAL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CHARCOAL MEDICINAL",
        "rr": 1.45,
        "risk_count": 31241,
        "predisposition_and_risk": 61,
        "risk_duration": 20973729,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCAGON",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLUCAGON",
        "rr": 1.45,
        "risk_count": 10481,
        "predisposition_and_risk": 19,
        "risk_duration": 22609294,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PACLITAXEL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PACLITAXEL",
        "rr": 1.44,
        "risk_count": 6286,
        "predisposition_and_risk": 11,
        "risk_duration": 23142045,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SELENIUM_COMPOUNDS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.44,
        "risk_count": 24613,
        "predisposition_and_risk": 43,
        "risk_duration": 26520846,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRICLOSAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.44,
        "risk_count": 33847,
        "predisposition_and_risk": 62,
        "risk_duration": 25273205,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BLEPHAMIDE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BLEPHAMIDE CD",
        "rr": 1.44,
        "risk_count": 12705,
        "predisposition_and_risk": 21,
        "risk_duration": 28015822,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GEMCITABINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GEMCITABINE",
        "rr": 1.44,
        "risk_count": 16230,
        "predisposition_and_risk": 27,
        "risk_duration": 27866035,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLOVE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLOVE",
        "rr": 1.44,
        "risk_count": 33960,
        "predisposition_and_risk": 60,
        "risk_duration": 26333578,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PENCICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PENCICLOVIR",
        "rr": 1.43,
        "risk_count": 8974,
        "predisposition_and_risk": 16,
        "risk_duration": 22677139,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SILVER_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.43,
        "risk_count": 11643,
        "predisposition_and_risk": 19,
        "risk_duration": 28260175,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASPIRIN.2DLYSINE_ACETYLSALICYLATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASPIRIN-LYSINE ACETYLSALICYLATE",
        "rr": 1.43,
        "risk_count": 48923,
        "predisposition_and_risk": 89,
        "risk_duration": 25392444,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BUTENAFINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BUTENAFINE",
        "rr": 1.43,
        "risk_count": 19509,
        "predisposition_and_risk": 33,
        "risk_duration": 27293234,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CICLODERM.2DC_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CICLODERM-C CD",
        "rr": 1.43,
        "risk_count": 15657,
        "predisposition_and_risk": 26,
        "risk_duration": 27672683,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TALC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.42,
        "risk_count": 16394,
        "predisposition_and_risk": 27,
        "risk_duration": 27701741,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FOSFOMYCIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FOSFOMYCIN",
        "rr": 1.42,
        "risk_count": 22679,
        "predisposition_and_risk": 38,
        "risk_duration": 27292341,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLYCOPYRRONIUM_BROMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLYCOPYRRONIUM BROMIDE",
        "rr": 1.42,
        "risk_count": 10834,
        "predisposition_and_risk": 19,
        "risk_duration": 22896978,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SOLIFENACIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.41,
        "risk_count": 47539,
        "predisposition_and_risk": 92,
        "risk_duration": 20572301,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZINCOD_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.41,
        "risk_count": 21618,
        "predisposition_and_risk": 36,
        "risk_duration": 27191190,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BICALUTAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BICALUTAMIDE",
        "rr": 1.41,
        "risk_count": 19241,
        "predisposition_and_risk": 34,
        "risk_duration": 22490678,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHOTREXATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHOTREXATE",
        "rr": 1.41,
        "risk_count": 36894,
        "predisposition_and_risk": 73,
        "risk_duration": 20038507,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NORTRIPTYLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NORTRIPTYLINE",
        "rr": 1.4,
        "risk_count": 10921,
        "predisposition_and_risk": 19,
        "risk_duration": 22689372,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OSMOLITE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OSMOLITE CD",
        "rr": 1.4,
        "risk_count": 21835,
        "predisposition_and_risk": 39,
        "risk_duration": 22039799,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXYBUTYNIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYBUTYNIN",
        "rr": 1.4,
        "risk_count": 40986,
        "predisposition_and_risk": 80,
        "risk_duration": 20255722,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TALC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.4,
        "risk_count": 9777,
        "predisposition_and_risk": 17,
        "risk_duration": 22710451,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BRONCHOLATE_PLUS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BRONCHOLATE PLUS CD",
        "rr": 1.4,
        "risk_count": 18756,
        "predisposition_and_risk": 34,
        "risk_duration": 21778750,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DONEPEZIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DONEPEZIL",
        "rr": 1.4,
        "risk_count": 20672,
        "predisposition_and_risk": 36,
        "risk_duration": 22659515,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EYE_CARE_WIPES",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EYE CARE WIPES",
        "rr": 1.4,
        "risk_count": 29247,
        "predisposition_and_risk": 49,
        "risk_duration": 26913256,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLUOROMETHOLONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLUOROMETHOLONE",
        "rr": 1.4,
        "risk_count": 23937,
        "predisposition_and_risk": 44,
        "risk_duration": 21484934,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MULTIDERM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MULTIDERM CD",
        "rr": 1.4,
        "risk_count": 7527,
        "predisposition_and_risk": 13,
        "risk_duration": 22914332,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NABUMETONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NABUMETONE",
        "rr": 1.4,
        "risk_count": 12403,
        "predisposition_and_risk": 22,
        "risk_duration": 22239502,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ABDOMINAL_BINDER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ABDOMINAL BINDER",
        "rr": 1.39,
        "risk_count": 9465,
        "predisposition_and_risk": 15,
        "risk_duration": 28248999,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMANTADINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AMANTADINE",
        "rr": 1.39,
        "risk_count": 45258,
        "predisposition_and_risk": 78,
        "risk_duration": 26068775,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SELEGILINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.39,
        "risk_count": 16360,
        "predisposition_and_risk": 26,
        "risk_duration": 28121604,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.XYLOMETAZOLINE.2DIPRATROPIUM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.39,
        "risk_count": 12062,
        "predisposition_and_risk": 21,
        "risk_duration": 22543662,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARBOSYLANE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CARBOSYLANE CD",
        "rr": 1.39,
        "risk_count": 16440,
        "predisposition_and_risk": 29,
        "risk_duration": 22210105,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FESOTERODINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FESOTERODINE",
        "rr": 1.39,
        "risk_count": 40748,
        "predisposition_and_risk": 75,
        "risk_duration": 21247227,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROCOLL_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROCOLL DRESSING",
        "rr": 1.39,
        "risk_count": 30523,
        "predisposition_and_risk": 51,
        "risk_duration": 26766687,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHYLPREDNISOLONE_.2D_LIDOCAINE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHYLPREDNISOLONE - LIDOCAINE CD",
        "rr": 1.39,
        "risk_count": 7595,
        "predisposition_and_risk": 13,
        "risk_duration": 22894140,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MONTELUKAST",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MONTELUKAST",
        "rr": 1.39,
        "risk_count": 62129,
        "predisposition_and_risk": 120,
        "risk_duration": 23162836,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACENOCOUMAROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACENOCOUMAROL",
        "rr": 1.38,
        "risk_count": 32123,
        "predisposition_and_risk": 54,
        "risk_duration": 26526793,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POVIDONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POVIDONE",
        "rr": 1.38,
        "risk_count": 7099,
        "predisposition_and_risk": 12,
        "risk_duration": 22974468,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RADIAN_B_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RADIAN B CD",
        "rr": 1.38,
        "risk_count": 26006,
        "predisposition_and_risk": 43,
        "risk_duration": 26890783,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.STOMA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.38,
        "risk_count": 60173,
        "predisposition_and_risk": 126,
        "risk_duration": 18659987,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIPOTRIOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALCIPOTRIOL",
        "rr": 1.38,
        "risk_count": 9502,
        "predisposition_and_risk": 15,
        "risk_duration": 28176001,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLOZAPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLOZAPINE",
        "rr": 1.38,
        "risk_count": 15727,
        "predisposition_and_risk": 29,
        "risk_duration": 21168030,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DEXPANTHENOL.2DSODIUM_HYALURONATE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXPANTHENOL-SODIUM HYALURONATE CD",
        "rr": 1.38,
        "risk_count": 9373,
        "predisposition_and_risk": 16,
        "risk_duration": 22885694,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOXYLAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOXYLAMINE",
        "rr": 1.38,
        "risk_count": 8224,
        "predisposition_and_risk": 14,
        "risk_duration": 22847493,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLOVE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLOVE",
        "rr": 1.38,
        "risk_count": 22874,
        "predisposition_and_risk": 41,
        "risk_duration": 21790215,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACETAZOLAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACETAZOLAMIDE",
        "rr": 1.37,
        "risk_count": 32654,
        "predisposition_and_risk": 60,
        "risk_duration": 21062511,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALENDRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ALENDRONIC ACID",
        "rr": 1.37,
        "risk_count": 80748,
        "predisposition_and_risk": 186,
        "risk_duration": 16759311,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXYCODONE_AND_PARACETAMOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXYCODONE AND PARACETAMOL",
        "rr": 1.37,
        "risk_count": 98195,
        "predisposition_and_risk": 229,
        "risk_duration": 18901115,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROBIOTIC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROBIOTIC",
        "rr": 1.37,
        "risk_count": 41893,
        "predisposition_and_risk": 72,
        "risk_duration": 25596745,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BECLOMETASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BECLOMETASONE",
        "rr": 1.37,
        "risk_count": 22241,
        "predisposition_and_risk": 36,
        "risk_duration": 27270472,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CIPROFIBRATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CIPROFIBRATE",
        "rr": 1.37,
        "risk_count": 60627,
        "predisposition_and_risk": 143,
        "risk_duration": 16376722,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLUCERNA_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLUCERNA CD",
        "rr": 1.37,
        "risk_count": 18927,
        "predisposition_and_risk": 30,
        "risk_duration": 27894037,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ISOCONAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ISOCONAZOLE",
        "rr": 1.37,
        "risk_count": 8817,
        "predisposition_and_risk": 15,
        "risk_duration": 22767921,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PENCICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PENCICLOVIR",
        "rr": 1.36,
        "risk_count": 18649,
        "predisposition_and_risk": 30,
        "risk_duration": 27157107,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROPAFENONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROPAFENONE",
        "rr": 1.36,
        "risk_count": 106120,
        "predisposition_and_risk": 219,
        "risk_duration": 21267730,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SALMETEROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.36,
        "risk_count": 24903,
        "predisposition_and_risk": 44,
        "risk_duration": 21746804,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CETIRIZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CETIRIZINE",
        "rr": 1.36,
        "risk_count": 76135,
        "predisposition_and_risk": 165,
        "risk_duration": 20228800,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DULAGLUTIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DULAGLUTIDE",
        "rr": 1.36,
        "risk_count": 34778,
        "predisposition_and_risk": 58,
        "risk_duration": 26178814,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FUNGIMON.2FUNDECYL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FUNGIMON/UNDECYL CD",
        "rr": 1.36,
        "risk_count": 36423,
        "predisposition_and_risk": 63,
        "risk_duration": 25371492,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GENTAMICIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GENTAMICIN",
        "rr": 1.36,
        "risk_count": 44813,
        "predisposition_and_risk": 89,
        "risk_duration": 19391340,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INHALER_PARTS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INHALER PARTS",
        "rr": 1.36,
        "risk_count": 17848,
        "predisposition_and_risk": 31,
        "risk_duration": 22135607,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KNEE_SHOTS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "KNEE SHOTS",
        "rr": 1.36,
        "risk_count": 7826,
        "predisposition_and_risk": 12,
        "risk_duration": 28573121,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LEVETIRACETAM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LEVETIRACETAM",
        "rr": 1.36,
        "risk_count": 28037,
        "predisposition_and_risk": 51,
        "risk_duration": 21042584,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MULTIVITAMINS_FOR_OCULAR_USE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MULTIVITAMINS FOR OCULAR USE",
        "rr": 1.36,
        "risk_count": 36532,
        "predisposition_and_risk": 66,
        "risk_duration": 21218593,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RADIAN_B_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RADIAN B CD",
        "rr": 1.35,
        "risk_count": 14607,
        "predisposition_and_risk": 25,
        "risk_duration": 22252966,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DULAGLUTIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DULAGLUTIDE",
        "rr": 1.35,
        "risk_count": 26572,
        "predisposition_and_risk": 47,
        "risk_duration": 21528496,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LIQUID_PARAFFIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LIQUID PARAFFIN",
        "rr": 1.35,
        "risk_count": 55347,
        "predisposition_and_risk": 99,
        "risk_duration": 24331646,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHOXY_POLYETHYLENE_GLYCOL.2DEPOETIN_BETA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA",
        "rr": 1.35,
        "risk_count": 25652,
        "predisposition_and_risk": 41,
        "risk_duration": 27302885,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MULTIVITAMINS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MULTIVITAMINS CD",
        "rr": 1.35,
        "risk_count": 7823,
        "predisposition_and_risk": 12,
        "risk_duration": 28287072,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.APIXABAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "APIXABAN",
        "rr": 1.34,
        "risk_count": 78040,
        "predisposition_and_risk": 153,
        "risk_duration": 19225539,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POLYSTYRENE_SULFONATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POLYSTYRENE SULFONATE",
        "rr": 1.34,
        "risk_count": 62252,
        "predisposition_and_risk": 127,
        "risk_duration": 18586121,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TERAZOSIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.34,
        "risk_count": 65482,
        "predisposition_and_risk": 130,
        "risk_duration": 18999380,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TERPENES_COMP_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.34,
        "risk_count": 27148,
        "predisposition_and_risk": 44,
        "risk_duration": 26724139,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ATRAUMAN_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ATRAUMAN DRESSING",
        "rr": 1.34,
        "risk_count": 14167,
        "predisposition_and_risk": 22,
        "risk_duration": 27888436,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FOAM_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FOAM DRESSING",
        "rr": 1.34,
        "risk_count": 51671,
        "predisposition_and_risk": 102,
        "risk_duration": 19170226,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KETOPROFEN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "KETOPROFEN",
        "rr": 1.34,
        "risk_count": 6697,
        "predisposition_and_risk": 11,
        "risk_duration": 23000561,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MINOCYCLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MINOCYCLINE",
        "rr": 1.34,
        "risk_count": 9722,
        "predisposition_and_risk": 15,
        "risk_duration": 27935462,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PREDNISOLONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PREDNISOLONE",
        "rr": 1.33,
        "risk_count": 46057,
        "predisposition_and_risk": 86,
        "risk_duration": 20059070,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TACROLIMUS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.33,
        "risk_count": 52430,
        "predisposition_and_risk": 95,
        "risk_duration": 23689896,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCOSE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLUCOSE",
        "rr": 1.33,
        "risk_count": 7334,
        "predisposition_and_risk": 12,
        "risk_duration": 22901600,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALPHOSYL_.22.222_IN_1.22.22_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ALPHOSYL \"\"2 IN 1\"\" CD",
        "rr": 1.32,
        "risk_count": 13211,
        "predisposition_and_risk": 22,
        "risk_duration": 22378293,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RENNIE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RENNIE CD",
        "rr": 1.32,
        "risk_count": 28749,
        "predisposition_and_risk": 46,
        "risk_duration": 26561429,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SODIUM_CL_FOR_IRRIGATION",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.32,
        "risk_count": 8034,
        "predisposition_and_risk": 13,
        "risk_duration": 22947911,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VITAMIN_A.2BD_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.32,
        "risk_count": 9927,
        "predisposition_and_risk": 15,
        "risk_duration": 28107872,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ATORVASTATIN_AND_EZETIMIBE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ATORVASTATIN AND EZETIMIBE",
        "rr": 1.32,
        "risk_count": 12101,
        "predisposition_and_risk": 20,
        "risk_duration": 22512727,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLEAN.2DEARS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLEAN-EARS CD",
        "rr": 1.32,
        "risk_count": 14954,
        "predisposition_and_risk": 25,
        "risk_duration": 22235115,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ETANERCEPT",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ETANERCEPT",
        "rr": 1.32,
        "risk_count": 25882,
        "predisposition_and_risk": 41,
        "risk_duration": 26751191,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLYCERIN.2DSORBITOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLYCERIN-SORBITOL CD",
        "rr": 1.32,
        "risk_count": 21845,
        "predisposition_and_risk": 37,
        "risk_duration": 21996320,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEFLUNOMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LEFLUNOMIDE",
        "rr": 1.32,
        "risk_count": 17057,
        "predisposition_and_risk": 26,
        "risk_duration": 27879922,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LINAGLIPTIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LINAGLIPTIN",
        "rr": 1.32,
        "risk_count": 50756,
        "predisposition_and_risk": 92,
        "risk_duration": 20482129,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AGIOLAX_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AGIOLAX CD",
        "rr": 1.31,
        "risk_count": 44160,
        "predisposition_and_risk": 81,
        "risk_duration": 20186441,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PARACETAMOL.2C_COMBINATIONS_EXCL.2E_PSYCHOLEPTIC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTIC",
        "rr": 1.31,
        "risk_count": 25451,
        "predisposition_and_risk": 45,
        "risk_duration": 20961218,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POVIDONE_COMP_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POVIDONE COMP CD",
        "rr": 1.31,
        "risk_count": 44116,
        "predisposition_and_risk": 73,
        "risk_duration": 25578917,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BLEPHAMIDE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BLEPHAMIDE CD",
        "rr": 1.31,
        "risk_count": 8637,
        "predisposition_and_risk": 14,
        "risk_duration": 22839117,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BLOOD_PRESSURE_MONITOR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BLOOD PRESSURE MONITOR",
        "rr": 1.31,
        "risk_count": 47224,
        "predisposition_and_risk": 81,
        "risk_duration": 24514831,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INHALER",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INHALER",
        "rr": 1.31,
        "risk_count": 8719,
        "predisposition_and_risk": 13,
        "risk_duration": 28329785,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHOXY_POLYETHYLENE_GLYCOL.2DEPOETIN_BETA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA",
        "rr": 1.31,
        "risk_count": 29659,
        "predisposition_and_risk": 52,
        "risk_duration": 21149536,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RENNIE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RENNIE CD",
        "rr": 1.3,
        "risk_count": 21917,
        "predisposition_and_risk": 37,
        "risk_duration": 21727413,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RIVASTIGMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RIVASTIGMINE",
        "rr": 1.3,
        "risk_count": 22074,
        "predisposition_and_risk": 33,
        "risk_duration": 28081265,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SULFACETAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.3,
        "risk_count": 19664,
        "predisposition_and_risk": 30,
        "risk_duration": 27403674,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DRONEDARONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DRONEDARONE",
        "rr": 1.3,
        "risk_count": 17496,
        "predisposition_and_risk": 26,
        "risk_duration": 28249483,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LAXATIVE_COMP.2E_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LAXATIVE COMP. CD",
        "rr": 1.3,
        "risk_count": 17071,
        "predisposition_and_risk": 28,
        "risk_duration": 22361795,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LOMEFLOXACIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LOMEFLOXACIN",
        "rr": 1.3,
        "risk_count": 14125,
        "predisposition_and_risk": 23,
        "risk_duration": 22450813,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.OXCARBAZEPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXCARBAZEPINE",
        "rr": 1.29,
        "risk_count": 11216,
        "predisposition_and_risk": 18,
        "risk_duration": 22650313,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PIOGLITAZONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PIOGLITAZONE",
        "rr": 1.29,
        "risk_count": 8783,
        "predisposition_and_risk": 14,
        "risk_duration": 22842724,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TALC.2D_ZINC_OXIDE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.29,
        "risk_count": 17875,
        "predisposition_and_risk": 27,
        "risk_duration": 27546558,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.JEVITY_LIQ.2E_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "JEVITY LIQ. CD",
        "rr": 1.29,
        "risk_count": 17076,
        "predisposition_and_risk": 28,
        "risk_duration": 22243500,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHENAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHENAMINE",
        "rr": 1.29,
        "risk_count": 12457,
        "predisposition_and_risk": 20,
        "risk_duration": 22655049,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PYRIDOSTIGMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PYRIDOSTIGMINE",
        "rr": 1.28,
        "risk_count": 15501,
        "predisposition_and_risk": 23,
        "risk_duration": 27855636,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RISEDRONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RISEDRONIC ACID",
        "rr": 1.28,
        "risk_count": 59708,
        "predisposition_and_risk": 110,
        "risk_duration": 19656467,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TROSPIUM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.28,
        "risk_count": 60731,
        "predisposition_and_risk": 112,
        "risk_duration": 19538904,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ULTRALAN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.28,
        "risk_count": 19847,
        "predisposition_and_risk": 30,
        "risk_duration": 27312263,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHLORHEXIDINE_COMBINATIONS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CHLORHEXIDINE COMBINATIONS CD",
        "rr": 1.28,
        "risk_count": 29751,
        "predisposition_and_risk": 51,
        "risk_duration": 21055493,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DRONEDARONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DRONEDARONE",
        "rr": 1.28,
        "risk_count": 16942,
        "predisposition_and_risk": 27,
        "risk_duration": 22581302,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENSURE_PLUS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENSURE PLUS CD",
        "rr": 1.28,
        "risk_count": 84523,
        "predisposition_and_risk": 163,
        "risk_duration": 21384965,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FOLEX.2FFORIC.2FFOROL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FOLEX/FORIC/FOROL CD",
        "rr": 1.28,
        "risk_count": 75937,
        "predisposition_and_risk": 140,
        "risk_duration": 22370718,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FORMOTEROL_AND_BECLOMETASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FORMOTEROL AND BECLOMETASONE",
        "rr": 1.28,
        "risk_count": 8269,
        "predisposition_and_risk": 13,
        "risk_duration": 22971817,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HAND_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HAND BRACE",
        "rr": 1.28,
        "risk_count": 27166,
        "predisposition_and_risk": 47,
        "risk_duration": 20810296,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEVETIRACETAM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LEVETIRACETAM",
        "rr": 1.28,
        "risk_count": 32183,
        "predisposition_and_risk": 51,
        "risk_duration": 26087070,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PROCTOZORIN_.2D_N_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROCTOZORIN - N CD",
        "rr": 1.27,
        "risk_count": 15473,
        "predisposition_and_risk": 23,
        "risk_duration": 27576549,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.UMECLIDINIUM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.27,
        "risk_count": 14505,
        "predisposition_and_risk": 23,
        "risk_duration": 22640664,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CHLORHEXIDINE_COMBINATIONS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CHLORHEXIDINE COMBINATIONS CD",
        "rr": 1.27,
        "risk_count": 35925,
        "predisposition_and_risk": 57,
        "risk_duration": 25729700,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLOMIPRAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLOMIPRAMINE",
        "rr": 1.27,
        "risk_count": 48103,
        "predisposition_and_risk": 81,
        "risk_duration": 24303364,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MIANSERIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIANSERIN",
        "rr": 1.27,
        "risk_count": 23268,
        "predisposition_and_risk": 39,
        "risk_duration": 21406023,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SOTALOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.26,
        "risk_count": 55347,
        "predisposition_and_risk": 101,
        "risk_duration": 19522125,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SPASMALGIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.26,
        "risk_count": 58694,
        "predisposition_and_risk": 105,
        "risk_duration": 22636334,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ATRAUMAN_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ATRAUMAN DRESSING",
        "rr": 1.26,
        "risk_count": 12074,
        "predisposition_and_risk": 19,
        "risk_duration": 22554819,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ELASTIC_BANDAGE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ELASTIC BANDAGE",
        "rr": 1.26,
        "risk_count": 48898,
        "predisposition_and_risk": 80,
        "risk_duration": 24723959,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GAVISCON_ADVANCE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GAVISCON ADVANCE CD",
        "rr": 1.26,
        "risk_count": 14453,
        "predisposition_and_risk": 21,
        "risk_duration": 28037889,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID_.28VIT_C.29",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASCORBIC ACID (VIT C)",
        "rr": 1.25,
        "risk_count": 63720,
        "predisposition_and_risk": 110,
        "risk_duration": 23307342,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROCYCLIDINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROCYCLIDINE",
        "rr": 1.25,
        "risk_count": 8961,
        "predisposition_and_risk": 14,
        "risk_duration": 22651293,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CABERGOLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CABERGOLINE",
        "rr": 1.25,
        "risk_count": 18727,
        "predisposition_and_risk": 30,
        "risk_duration": 22017462,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARBOXYMETHYLCELLULOSE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CARBOXYMETHYLCELLULOSE",
        "rr": 1.25,
        "risk_count": 77579,
        "predisposition_and_risk": 138,
        "risk_duration": 22626249,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COD.2DGUAIACOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "COD-GUAIACOL CD",
        "rr": 1.25,
        "risk_count": 27273,
        "predisposition_and_risk": 46,
        "risk_duration": 20924379,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MEBEVERINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MEBEVERINE",
        "rr": 1.25,
        "risk_count": 29031,
        "predisposition_and_risk": 49,
        "risk_duration": 20897273,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ORACORT_E_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ORACORT E CD",
        "rr": 1.24,
        "risk_count": 70462,
        "predisposition_and_risk": 128,
        "risk_duration": 21948154,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PARACETAMOL.2C_COMBINATIONS_EXCL.2E_PSYCHOLEPTIC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTIC",
        "rr": 1.24,
        "risk_count": 43040,
        "predisposition_and_risk": 71,
        "risk_duration": 24141685,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PNEUMOCOCCUS.2C_PURIFIED_POLYSACHARIDES_ANTIGEN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PNEUMOCOCCUS, PURIFIED POLYSACHARIDES ANTIGEN",
        "rr": 1.24,
        "risk_count": 60967,
        "predisposition_and_risk": 99,
        "risk_duration": 24666080,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SALICYLIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.24,
        "risk_count": 39390,
        "predisposition_and_risk": 63,
        "risk_duration": 24895776,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VILANTEROL_AND_UMECLIDINIUM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.24,
        "risk_count": 12398,
        "predisposition_and_risk": 19,
        "risk_duration": 22788980,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METFORMIN_AND_LINAGLIPTIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METFORMIN AND LINAGLIPTIN CD",
        "rr": 1.24,
        "risk_count": 28156,
        "predisposition_and_risk": 45,
        "risk_duration": 21816088,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.AMANTADINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AMANTADINE",
        "rr": 1.23,
        "risk_count": 52813,
        "predisposition_and_risk": 91,
        "risk_duration": 20070669,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ARIPIPRAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ARIPIPRAZOLE",
        "rr": 1.23,
        "risk_count": 11317,
        "predisposition_and_risk": 16,
        "risk_duration": 28013014,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ORLISTAT",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ORLISTAT",
        "rr": 1.23,
        "risk_count": 18719,
        "predisposition_and_risk": 30,
        "risk_duration": 21691062,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VERUCID.2FVERRUMAL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.23,
        "risk_count": 13397,
        "predisposition_and_risk": 21,
        "risk_duration": 22130282,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BACLOFEN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BACLOFEN",
        "rr": 1.23,
        "risk_count": 40566,
        "predisposition_and_risk": 64,
        "risk_duration": 25049096,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BEVACIZUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BEVACIZUMAB",
        "rr": 1.23,
        "risk_count": 11460,
        "predisposition_and_risk": 16,
        "risk_duration": 28280817,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CROTAMITON",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CROTAMITON",
        "rr": 1.23,
        "risk_count": 23708,
        "predisposition_and_risk": 38,
        "risk_duration": 21612706,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAXITROL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAXITROL CD",
        "rr": 1.23,
        "risk_count": 68622,
        "predisposition_and_risk": 141,
        "risk_duration": 16940918,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MINOCYCLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MINOCYCLINE",
        "rr": 1.23,
        "risk_count": 10937,
        "predisposition_and_risk": 17,
        "risk_duration": 22364670,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PARACETAMOL.2DASPIRIN.2DCAFFEIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PARACETAMOL-ASPIRIN-CAFFEIN CD",
        "rr": 1.22,
        "risk_count": 32860,
        "predisposition_and_risk": 56,
        "risk_duration": 20136591,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIOTROPIUM_BROMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.22,
        "risk_count": 74537,
        "predisposition_and_risk": 128,
        "risk_duration": 22870669,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIETHYLTOLUAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DIETHYLTOLUAMIDE",
        "rr": 1.22,
        "risk_count": 18069,
        "predisposition_and_risk": 26,
        "risk_duration": 27412365,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EXAMINATION_GLOVES",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EXAMINATION GLOVES",
        "rr": 1.22,
        "risk_count": 22834,
        "predisposition_and_risk": 33,
        "risk_duration": 27280471,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FERRIC_OXIDE_POLYMALTOSE_COMPLEXES",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FERRIC OXIDE POLYMALTOSE COMPLEXES",
        "rr": 1.22,
        "risk_count": 57777,
        "predisposition_and_risk": 104,
        "risk_duration": 19136803,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FERROUS_CALCIUM_CITRATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FERROUS CALCIUM CITRATE",
        "rr": 1.22,
        "risk_count": 33445,
        "predisposition_and_risk": 55,
        "risk_duration": 21005725,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FLEXITOL_HAND",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLEXITOL HAND",
        "rr": 1.22,
        "risk_count": 7967,
        "predisposition_and_risk": 12,
        "risk_duration": 22873720,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INHALER_PARTS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INHALER PARTS",
        "rr": 1.22,
        "risk_count": 23964,
        "predisposition_and_risk": 35,
        "risk_duration": 26915950,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIDOCAINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LIDOCAINE",
        "rr": 1.22,
        "risk_count": 25907,
        "predisposition_and_risk": 42,
        "risk_duration": 21194389,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LIDOCAINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LIDOCAINE",
        "rr": 1.22,
        "risk_count": 32497,
        "predisposition_and_risk": 49,
        "risk_duration": 26044400,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALLOPURINOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ALLOPURINOL",
        "rr": 1.21,
        "risk_count": 131661,
        "predisposition_and_risk": 299,
        "risk_duration": 17135852,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PAPAVERINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PAPAVERINE",
        "rr": 1.21,
        "risk_count": 75441,
        "predisposition_and_risk": 142,
        "risk_duration": 20732118,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THREOLONE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.21,
        "risk_count": 30039,
        "predisposition_and_risk": 49,
        "risk_duration": 21006113,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VALGANCICLOVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.21,
        "risk_count": 8662,
        "predisposition_and_risk": 13,
        "risk_duration": 22710030,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CATHETER_SUPP.2E",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CATHETER SUPP.",
        "rr": 1.21,
        "risk_count": 36324,
        "predisposition_and_risk": 60,
        "risk_duration": 20738734,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.COMPRESSION_STOCKING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "COMPRESSION STOCKING",
        "rr": 1.21,
        "risk_count": 43395,
        "predisposition_and_risk": 68,
        "risk_duration": 24837078,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DABIGATRAN_ETEXILATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DABIGATRAN ETEXILATE",
        "rr": 1.21,
        "risk_count": 52725,
        "predisposition_and_risk": 78,
        "risk_duration": 26268991,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DRESSING",
        "rr": 1.21,
        "risk_count": 66974,
        "predisposition_and_risk": 131,
        "risk_duration": 17513019,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ELBOW_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ELBOW BRACE",
        "rr": 1.21,
        "risk_count": 9325,
        "predisposition_and_risk": 13,
        "risk_duration": 27951268,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ETANERCEPT",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ETANERCEPT",
        "rr": 1.21,
        "risk_count": 14876,
        "predisposition_and_risk": 23,
        "risk_duration": 22089503,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLUCOSE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLUCOSE",
        "rr": 1.21,
        "risk_count": 8015,
        "predisposition_and_risk": 11,
        "risk_duration": 28342811,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULINS_SYRINGE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULINS SYRINGE",
        "rr": 1.21,
        "risk_count": 46676,
        "predisposition_and_risk": 82,
        "risk_duration": 19473895,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ISPAGHULA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ISPAGHULA",
        "rr": 1.21,
        "risk_count": 29885,
        "predisposition_and_risk": 44,
        "risk_duration": 26467970,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NET_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NET DRESSING",
        "rr": 1.21,
        "risk_count": 26243,
        "predisposition_and_risk": 42,
        "risk_duration": 21311696,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NITRAZEPAM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NITRAZEPAM",
        "rr": 1.2,
        "risk_count": 34174,
        "predisposition_and_risk": 57,
        "risk_duration": 20229295,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SERTRALINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.2,
        "risk_count": 43417,
        "predisposition_and_risk": 76,
        "risk_duration": 19304419,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHLORPHENAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CHLORPHENAMINE",
        "rr": 1.2,
        "risk_count": 37545,
        "predisposition_and_risk": 62,
        "risk_duration": 20426460,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ELETRIPTAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ELETRIPTAN",
        "rr": 1.2,
        "risk_count": 10475,
        "predisposition_and_risk": 16,
        "risk_duration": 22148063,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ESOMEPRAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ESOMEPRAZOLE",
        "rr": 1.2,
        "risk_count": 95568,
        "predisposition_and_risk": 219,
        "risk_duration": 14719271,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FORMOTEROL_AND_FLUTICASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FORMOTEROL AND FLUTICASONE",
        "rr": 1.2,
        "risk_count": 10973,
        "predisposition_and_risk": 15,
        "risk_duration": 28300226,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDRALAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDRALAZINE",
        "rr": 1.2,
        "risk_count": 42752,
        "predisposition_and_risk": 70,
        "risk_duration": 20630453,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_DEGLUDEC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULIN DEGLUDEC",
        "rr": 1.2,
        "risk_count": 28032,
        "predisposition_and_risk": 40,
        "risk_duration": 27022640,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROCTOZORIN_.2D_N_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROCTOZORIN - N CD",
        "rr": 1.19,
        "risk_count": 10745,
        "predisposition_and_risk": 16,
        "risk_duration": 22472214,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RASAGILINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RASAGILINE",
        "rr": 1.19,
        "risk_count": 28582,
        "predisposition_and_risk": 40,
        "risk_duration": 27435471,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SULFASALAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.19,
        "risk_count": 32379,
        "predisposition_and_risk": 48,
        "risk_duration": 25854929,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRAVOPROST",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.19,
        "risk_count": 68267,
        "predisposition_and_risk": 108,
        "risk_duration": 24263762,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CALCIUM.2DMAGNESIUM.2BZINC_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALCIUM-MAGNESIUM+ZINC CD",
        "rr": 1.19,
        "risk_count": 12157,
        "predisposition_and_risk": 18,
        "risk_duration": 22666709,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CARBOXYMETHYLCELLULOSE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CARBOXYMETHYLCELLULOSE",
        "rr": 1.19,
        "risk_count": 37353,
        "predisposition_and_risk": 61,
        "risk_duration": 20645255,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FINGER_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FINGER DRESSING",
        "rr": 1.19,
        "risk_count": 31031,
        "predisposition_and_risk": 45,
        "risk_duration": 26412469,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEMANTINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MEMANTINE",
        "rr": 1.19,
        "risk_count": 20583,
        "predisposition_and_risk": 28,
        "risk_duration": 28098092,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NECK_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NECK BRACE",
        "rr": 1.19,
        "risk_count": 8885,
        "predisposition_and_risk": 12,
        "risk_duration": 28266953,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ACETAZOLAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACETAZOLAMIDE",
        "rr": 1.18,
        "risk_count": 41572,
        "predisposition_and_risk": 62,
        "risk_duration": 25489755,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RIVAROXABAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "RIVAROXABAN",
        "rr": 1.18,
        "risk_count": 73365,
        "predisposition_and_risk": 112,
        "risk_duration": 24889086,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SILICONE_PRODUCTS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.18,
        "risk_count": 10378,
        "predisposition_and_risk": 14,
        "risk_duration": 28167485,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TERBUTALINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.18,
        "risk_count": 53292,
        "predisposition_and_risk": 85,
        "risk_duration": 23854841,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BACK_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BACK BRACE",
        "rr": 1.18,
        "risk_count": 45456,
        "predisposition_and_risk": 71,
        "risk_duration": 24345400,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DAKTACORT_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DAKTACORT CD",
        "rr": 1.18,
        "risk_count": 21332,
        "predisposition_and_risk": 33,
        "risk_duration": 21560783,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROXYCHLOROQUINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROXYCHLOROQUINE",
        "rr": 1.18,
        "risk_count": 22598,
        "predisposition_and_risk": 35,
        "risk_duration": 21485365,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAPROTILINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAPROTILINE",
        "rr": 1.18,
        "risk_count": 28824,
        "predisposition_and_risk": 41,
        "risk_duration": 26833162,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METHYLPREDNISOLONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHYLPREDNISOLONE",
        "rr": 1.18,
        "risk_count": 35769,
        "predisposition_and_risk": 59,
        "risk_duration": 20109366,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PACLITAXEL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PACLITAXEL",
        "rr": 1.17,
        "risk_count": 27555,
        "predisposition_and_risk": 39,
        "risk_duration": 26649350,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SOY_ISOFLAVONES",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.17,
        "risk_count": 15351,
        "predisposition_and_risk": 22,
        "risk_duration": 26320416,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRAMADOL_AND_PARACETAMOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.17,
        "risk_count": 120040,
        "predisposition_and_risk": 269,
        "risk_duration": 16855424,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CLINDAMYCIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLINDAMYCIN",
        "rr": 1.17,
        "risk_count": 39101,
        "predisposition_and_risk": 66,
        "risk_duration": 19597110,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EASY_IRON_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EASY IRON CD",
        "rr": 1.17,
        "risk_count": 78105,
        "predisposition_and_risk": 132,
        "risk_duration": 22310562,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EUCALYPTUS_OIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EUCALYPTUS OIL",
        "rr": 1.17,
        "risk_count": 13940,
        "predisposition_and_risk": 19,
        "risk_duration": 27751237,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GEMCITABINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GEMCITABINE",
        "rr": 1.17,
        "risk_count": 14349,
        "predisposition_and_risk": 21,
        "risk_duration": 22631448,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYPERICI_HERBA",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYPERICI HERBA",
        "rr": 1.17,
        "risk_count": 47133,
        "predisposition_and_risk": 71,
        "risk_duration": 24965043,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_SOLUBLE_.28HUMAN.29",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULIN SOLUBLE (HUMAN)",
        "rr": 1.17,
        "risk_count": 50878,
        "predisposition_and_risk": 92,
        "risk_duration": 18238766,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LOTEPREDNOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LOTEPREDNOL",
        "rr": 1.17,
        "risk_count": 14815,
        "predisposition_and_risk": 20,
        "risk_duration": 27900009,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAGNESIUM_HYDROXIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAGNESIUM HYDROXIDE",
        "rr": 1.17,
        "risk_count": 20190,
        "predisposition_and_risk": 30,
        "risk_duration": 22270870,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMOROLFINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "AMOROLFINE",
        "rr": 1.16,
        "risk_count": 29723,
        "predisposition_and_risk": 42,
        "risk_duration": 26372971,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OSMOLITE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OSMOLITE CD",
        "rr": 1.16,
        "risk_count": 18520,
        "predisposition_and_risk": 25,
        "risk_duration": 27667910,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.WATER_FOR_IRRIGATION",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.16,
        "risk_count": 74247,
        "predisposition_and_risk": 125,
        "risk_duration": 22264127,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CATHETER_SUPP.2E",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CATHETER SUPP.",
        "rr": 1.16,
        "risk_count": 35613,
        "predisposition_and_risk": 51,
        "risk_duration": 26206070,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CHLORPHENAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CHLORPHENAMINE",
        "rr": 1.16,
        "risk_count": 61322,
        "predisposition_and_risk": 97,
        "risk_duration": 23709914,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CROMOGLICIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CROMOGLICIC ACID",
        "rr": 1.16,
        "risk_count": 11059,
        "predisposition_and_risk": 16,
        "risk_duration": 22545595,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXEFRIN.2FDETHAPHRINE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXEFRIN/DETHAPHRINE CD",
        "rr": 1.16,
        "risk_count": 20210,
        "predisposition_and_risk": 28,
        "risk_duration": 27030523,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCOSAMINE.2BCHONDROIT.2E_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLUCOSAMINE+CHONDROIT. CD",
        "rr": 1.16,
        "risk_count": 25073,
        "predisposition_and_risk": 38,
        "risk_duration": 21609604,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYALURONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYALURONIC ACID",
        "rr": 1.16,
        "risk_count": 102694,
        "predisposition_and_risk": 191,
        "risk_duration": 20136182,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.JEVITY_LIQ.2E_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "JEVITY LIQ. CD",
        "rr": 1.16,
        "risk_count": 15760,
        "predisposition_and_risk": 21,
        "risk_duration": 27969848,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LETROZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LETROZOLE",
        "rr": 1.16,
        "risk_count": 76880,
        "predisposition_and_risk": 128,
        "risk_duration": 22363552,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MILNACIPRAN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MILNACIPRAN",
        "rr": 1.16,
        "risk_count": 26827,
        "predisposition_and_risk": 38,
        "risk_duration": 26468352,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OPTRYL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OPTRYL CD",
        "rr": 1.15,
        "risk_count": 28989,
        "predisposition_and_risk": 40,
        "risk_duration": 26881774,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TAROCIDIN.2FPHENIMIXIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.15,
        "risk_count": 40619,
        "predisposition_and_risk": 67,
        "risk_duration": 19612330,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIOCTIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.15,
        "risk_count": 45459,
        "predisposition_and_risk": 73,
        "risk_duration": 20196867,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BACK_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BACK BRACE",
        "rr": 1.15,
        "risk_count": 32553,
        "predisposition_and_risk": 52,
        "risk_duration": 20331004,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CAST",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CAST",
        "rr": 1.15,
        "risk_count": 34013,
        "predisposition_and_risk": 54,
        "risk_duration": 20519260,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FERRIC_HYDROXIDE_POLYMALTOSE_COMPLEX",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FERRIC HYDROXIDE POLYMALTOSE COMPLEX",
        "rr": 1.15,
        "risk_count": 10657,
        "predisposition_and_risk": 14,
        "risk_duration": 28202352,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUVASTATIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLUVASTATIN",
        "rr": 1.15,
        "risk_count": 8468,
        "predisposition_and_risk": 11,
        "risk_duration": 28456336,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYALURONIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYALURONIC ACID",
        "rr": 1.15,
        "risk_count": 47801,
        "predisposition_and_risk": 78,
        "risk_duration": 19932666,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYALURONIC_ACID.2DLACTIC_ACID.2DUREA_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYALURONIC ACID-LACTIC ACID-UREA CD",
        "rr": 1.15,
        "risk_count": 44311,
        "predisposition_and_risk": 65,
        "risk_duration": 25220381,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MAGNESIUM_OXIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAGNESIUM OXIDE",
        "rr": 1.15,
        "risk_count": 71792,
        "predisposition_and_risk": 111,
        "risk_duration": 24034591,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MERFEN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MERFEN CD",
        "rr": 1.15,
        "risk_count": 32243,
        "predisposition_and_risk": 51,
        "risk_duration": 20510601,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACENOCOUMAROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACENOCOUMAROL",
        "rr": 1.14,
        "risk_count": 25712,
        "predisposition_and_risk": 38,
        "risk_duration": 21701424,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SAXAGLIPTIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.14,
        "risk_count": 16817,
        "predisposition_and_risk": 22,
        "risk_duration": 28149494,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TROXERUTIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.14,
        "risk_count": 17829,
        "predisposition_and_risk": 26,
        "risk_duration": 22146667,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.URINE_BAG",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.14,
        "risk_count": 35287,
        "predisposition_and_risk": 49,
        "risk_duration": 26537362,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.WATER_FOR_INJECTION",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.14,
        "risk_count": 16075,
        "predisposition_and_risk": 21,
        "risk_duration": 28049149,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ATROPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ATROPINE",
        "rr": 1.14,
        "risk_count": 12650,
        "predisposition_and_risk": 18,
        "risk_duration": 22666796,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BENZATHINE_BENZYLPENICILLIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BENZATHINE BENZYLPENICILLIN",
        "rr": 1.14,
        "risk_count": 31389,
        "predisposition_and_risk": 48,
        "risk_duration": 20975943,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CAST",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CAST",
        "rr": 1.14,
        "risk_count": 41966,
        "predisposition_and_risk": 61,
        "risk_duration": 25203433,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CEFTRIAXONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CEFTRIAXONE",
        "rr": 1.14,
        "risk_count": 13033,
        "predisposition_and_risk": 17,
        "risk_duration": 28135421,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXPANTHENOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXPANTHENOL",
        "rr": 1.14,
        "risk_count": 35267,
        "predisposition_and_risk": 50,
        "risk_duration": 25805807,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOXYCYCLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOXYCYCLINE",
        "rr": 1.14,
        "risk_count": 81160,
        "predisposition_and_risk": 151,
        "risk_duration": 19751753,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENALAPRIL_AND_LERCANIDIPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENALAPRIL AND LERCANIDIPINE",
        "rr": 1.14,
        "risk_count": 80383,
        "predisposition_and_risk": 157,
        "risk_duration": 16503854,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENTECAVIR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENTECAVIR",
        "rr": 1.14,
        "risk_count": 11171,
        "predisposition_and_risk": 16,
        "risk_duration": 22406817,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KERATOSPOR_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "KERATOSPOR CD",
        "rr": 1.14,
        "risk_count": 11904,
        "predisposition_and_risk": 17,
        "risk_duration": 22543060,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LARGE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LARGE",
        "rr": 1.14,
        "risk_count": 33210,
        "predisposition_and_risk": 50,
        "risk_duration": 21282141,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METRONIDAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METRONIDAZOLE",
        "rr": 1.14,
        "risk_count": 42760,
        "predisposition_and_risk": 72,
        "risk_duration": 19181657,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MINOXIDIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MINOXIDIL",
        "rr": 1.14,
        "risk_count": 10534,
        "predisposition_and_risk": 15,
        "risk_duration": 22685649,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACIDOPHILUS_PROBIOTIC_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACIDOPHILUS PROBIOTIC CD",
        "rr": 1.13,
        "risk_count": 41111,
        "predisposition_and_risk": 65,
        "risk_duration": 20212424,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ACITRETIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ACITRETIN",
        "rr": 1.13,
        "risk_count": 20541,
        "predisposition_and_risk": 30,
        "risk_duration": 21799741,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID_AND_CALCIUM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASCORBIC ACID AND CALCIUM CD",
        "rr": 1.13,
        "risk_count": 25418,
        "predisposition_and_risk": 34,
        "risk_duration": 27229630,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SPASMALGIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.13,
        "risk_count": 36389,
        "predisposition_and_risk": 59,
        "risk_duration": 19702461,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THIAMINE_.28VIT.2E_B1.29",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.13,
        "risk_count": 29777,
        "predisposition_and_risk": 45,
        "risk_duration": 21188364,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BUPRENORPHINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BUPRENORPHINE",
        "rr": 1.13,
        "risk_count": 22550,
        "predisposition_and_risk": 33,
        "risk_duration": 21795320,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BUPROPION",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BUPROPION",
        "rr": 1.13,
        "risk_count": 25125,
        "predisposition_and_risk": 38,
        "risk_duration": 21175281,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIFLUCORTOLONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DIFLUCORTOLONE",
        "rr": 1.13,
        "risk_count": 52144,
        "predisposition_and_risk": 80,
        "risk_duration": 23798105,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IBUPROPHEN_.2D_PSEUDOEPHEDRINE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IBUPROPHEN - PSEUDOEPHEDRINE CD",
        "rr": 1.13,
        "risk_count": 14239,
        "predisposition_and_risk": 19,
        "risk_duration": 27320535,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METFORMIN_AND_LINAGLIPTIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METFORMIN AND LINAGLIPTIN CD",
        "rr": 1.13,
        "risk_count": 22795,
        "predisposition_and_risk": 30,
        "risk_duration": 27546196,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ANESTHETIC.2FOTIDIN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ANESTHETIC/OTIDIN CD",
        "rr": 1.12,
        "risk_count": 39328,
        "predisposition_and_risk": 64,
        "risk_duration": 19444301,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PENTOXIFYLLINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PENTOXIFYLLINE",
        "rr": 1.12,
        "risk_count": 41347,
        "predisposition_and_risk": 57,
        "risk_duration": 26086073,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SENNOSIDES_A.2BB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.12,
        "risk_count": 38700,
        "predisposition_and_risk": 54,
        "risk_duration": 25936571,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EASY_IRON_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EASY IRON CD",
        "rr": 1.12,
        "risk_count": 54882,
        "predisposition_and_risk": 90,
        "risk_duration": 19312828,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ELASTIC_BANDAGE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ELASTIC BANDAGE",
        "rr": 1.12,
        "risk_count": 41403,
        "predisposition_and_risk": 66,
        "risk_duration": 19900707,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FERRIFOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FERRIFOL CD",
        "rr": 1.12,
        "risk_count": 45703,
        "predisposition_and_risk": 71,
        "risk_duration": 20262716,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HEPATITIS_B_VACCINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HEPATITIS B VACCINE",
        "rr": 1.12,
        "risk_count": 24258,
        "predisposition_and_risk": 33,
        "risk_duration": 26504047,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KALGARON_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "KALGARON CD",
        "rr": 1.12,
        "risk_count": 30165,
        "predisposition_and_risk": 47,
        "risk_duration": 20330186,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NICOTINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NICOTINE",
        "rr": 1.12,
        "risk_count": 31817,
        "predisposition_and_risk": 50,
        "risk_duration": 20064093,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POVIDONE_COMP_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POVIDONE COMP CD",
        "rr": 1.11,
        "risk_count": 20409,
        "predisposition_and_risk": 29,
        "risk_duration": 22014521,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PRASUGREL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PRASUGREL",
        "rr": 1.11,
        "risk_count": 34478,
        "predisposition_and_risk": 54,
        "risk_duration": 19909588,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TICAGRELOR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.11,
        "risk_count": 14824,
        "predisposition_and_risk": 19,
        "risk_duration": 27971378,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ATROPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ATROPINE",
        "rr": 1.11,
        "risk_count": 11080,
        "predisposition_and_risk": 14,
        "risk_duration": 28265399,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FERROUS_SULFATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FERROUS SULFATE",
        "rr": 1.11,
        "risk_count": 95129,
        "predisposition_and_risk": 199,
        "risk_duration": 14991505,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FUNGIMON.2FUNDECYL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FUNGIMON/UNDECYL CD",
        "rr": 1.11,
        "risk_count": 33559,
        "predisposition_and_risk": 52,
        "risk_duration": 20232873,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_SYRINGE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULIN SYRINGE",
        "rr": 1.11,
        "risk_count": 36512,
        "predisposition_and_risk": 50,
        "risk_duration": 26206214,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LACTULOSE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LACTULOSE",
        "rr": 1.11,
        "risk_count": 131628,
        "predisposition_and_risk": 282,
        "risk_duration": 16626024,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NABUMETONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NABUMETONE",
        "rr": 1.11,
        "risk_count": 32223,
        "predisposition_and_risk": 45,
        "risk_duration": 25626437,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ANKLE_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ANKLE BRACE",
        "rr": 1.1,
        "risk_count": 19573,
        "predisposition_and_risk": 28,
        "risk_duration": 21667459,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PANCRELIPASE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PANCRELIPASE",
        "rr": 1.1,
        "risk_count": 21895,
        "predisposition_and_risk": 31,
        "risk_duration": 21911164,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2DBIMATOPROST_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.1,
        "risk_count": 9637,
        "predisposition_and_risk": 12,
        "risk_duration": 28554716,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TOBRAMYCIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.1,
        "risk_count": 23565,
        "predisposition_and_risk": 34,
        "risk_duration": 21511175,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.VILANTEROL_AND_FLUTICASONE_FUROATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.1,
        "risk_count": 50766,
        "predisposition_and_risk": 80,
        "risk_duration": 19782193,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BALNEUM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BALNEUM CD",
        "rr": 1.1,
        "risk_count": 24447,
        "predisposition_and_risk": 32,
        "risk_duration": 27009946,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BECLOMETASONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BECLOMETASONE",
        "rr": 1.1,
        "risk_count": 15898,
        "predisposition_and_risk": 22,
        "risk_duration": 22352531,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CANDESARTAN_.2D_HYDROCHLOROTHIAZIDE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CANDESARTAN - HYDROCHLOROTHIAZIDE CD",
        "rr": 1.1,
        "risk_count": 82161,
        "predisposition_and_risk": 125,
        "risk_duration": 23383816,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CAPSAICIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CAPSAICIN",
        "rr": 1.1,
        "risk_count": 57181,
        "predisposition_and_risk": 87,
        "risk_duration": 23384641,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.COLCHICINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "COLCHICINE",
        "rr": 1.1,
        "risk_count": 86614,
        "predisposition_and_risk": 152,
        "risk_duration": 20193741,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOXEPIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOXEPIN",
        "rr": 1.1,
        "risk_count": 25998,
        "predisposition_and_risk": 34,
        "risk_duration": 27171710,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROXYZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROXYZINE",
        "rr": 1.1,
        "risk_count": 15836,
        "predisposition_and_risk": 22,
        "risk_duration": 22244794,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_SOLUBLE_.28HUMAN.29",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULIN SOLUBLE (HUMAN)",
        "rr": 1.1,
        "risk_count": 49704,
        "predisposition_and_risk": 73,
        "risk_duration": 24197714,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METHENAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METHENAMINE",
        "rr": 1.1,
        "risk_count": 23194,
        "predisposition_and_risk": 30,
        "risk_duration": 27475410,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NET_DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NET DRESSING",
        "rr": 1.1,
        "risk_count": 30578,
        "predisposition_and_risk": 41,
        "risk_duration": 26438031,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ALENDRONIC_ACID.2C_AND_COLECALCIFEROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ALENDRONIC ACID, AND COLECALCIFEROL",
        "rr": 1.09,
        "risk_count": 13992,
        "predisposition_and_risk": 19,
        "risk_duration": 22699308,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NITROFURANTOIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NITROFURANTOIN",
        "rr": 1.09,
        "risk_count": 24754,
        "predisposition_and_risk": 35,
        "risk_duration": 21672196,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROBIOTIC",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROBIOTIC",
        "rr": 1.09,
        "risk_count": 13189,
        "predisposition_and_risk": 18,
        "risk_duration": 22587251,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TRAMADOL_AND_PARACETAMOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.09,
        "risk_count": 77420,
        "predisposition_and_risk": 145,
        "risk_duration": 16455050,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOXYLAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOXYLAMINE",
        "rr": 1.09,
        "risk_count": 14212,
        "predisposition_and_risk": 18,
        "risk_duration": 27733520,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PRAMIPEXOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PRAMIPEXOLE",
        "rr": 1.08,
        "risk_count": 13777,
        "predisposition_and_risk": 17,
        "risk_duration": 28315406,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROMETHAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PROMETHAZINE",
        "rr": 1.08,
        "risk_count": 45251,
        "predisposition_and_risk": 76,
        "risk_duration": 18173773,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SODIUM_CHLORIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.08,
        "risk_count": 110894,
        "predisposition_and_risk": 233,
        "risk_duration": 16605211,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.THIORIDAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.08,
        "risk_count": 21547,
        "predisposition_and_risk": 31,
        "risk_duration": 21170460,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.VILDAGLIPTIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.08,
        "risk_count": 36156,
        "predisposition_and_risk": 47,
        "risk_duration": 26864160,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CALCIUM_GLUBIONATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CALCIUM GLUBIONATE",
        "rr": 1.08,
        "risk_count": 72512,
        "predisposition_and_risk": 109,
        "risk_duration": 23104079,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLOTIAPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLOTIAPINE",
        "rr": 1.08,
        "risk_count": 38138,
        "predisposition_and_risk": 55,
        "risk_duration": 24058719,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FOLEX.2FFORIC.2FFOROL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FOLEX/FORIC/FOROL CD",
        "rr": 1.08,
        "risk_count": 51109,
        "predisposition_and_risk": 79,
        "risk_duration": 19721504,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLYCERYL_TRINITRATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLYCERYL TRINITRATE",
        "rr": 1.08,
        "risk_count": 20693,
        "predisposition_and_risk": 26,
        "risk_duration": 27648024,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HAND_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HAND BRACE",
        "rr": 1.08,
        "risk_count": 41493,
        "predisposition_and_risk": 59,
        "risk_duration": 24454097,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.HYDROCORTISONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROCORTISONE",
        "rr": 1.08,
        "risk_count": 18713,
        "predisposition_and_risk": 26,
        "risk_duration": 21852248,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROCORTISONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROCORTISONE",
        "rr": 1.08,
        "risk_count": 23906,
        "predisposition_and_risk": 31,
        "risk_duration": 26806561,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IMIPRAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "IMIPRAMINE",
        "rr": 1.08,
        "risk_count": 24039,
        "predisposition_and_risk": 31,
        "risk_duration": 26976757,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KERATOSPOR_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "KERATOSPOR CD",
        "rr": 1.08,
        "risk_count": 19631,
        "predisposition_and_risk": 25,
        "risk_duration": 27295109,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KETOTIFEN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "KETOTIFEN",
        "rr": 1.08,
        "risk_count": 23452,
        "predisposition_and_risk": 30,
        "risk_duration": 27133817,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MELATONIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MELATONIN",
        "rr": 1.08,
        "risk_count": 33931,
        "predisposition_and_risk": 44,
        "risk_duration": 26851515,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METOLAZONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METOLAZONE",
        "rr": 1.08,
        "risk_count": 45168,
        "predisposition_and_risk": 68,
        "risk_duration": 20174508,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METRONIDAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METRONIDAZOLE",
        "rr": 1.08,
        "risk_count": 59105,
        "predisposition_and_risk": 95,
        "risk_duration": 21612609,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASCORBIC_ACID_.28VIT_C.29",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASCORBIC ACID (VIT C)",
        "rr": 1.07,
        "risk_count": 44270,
        "predisposition_and_risk": 68,
        "risk_duration": 19614395,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASCORBIC_ACID.2DPROPOLIS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASCORBIC ACID-PROPOLIS CD",
        "rr": 1.07,
        "risk_count": 8345,
        "predisposition_and_risk": 11,
        "risk_duration": 22845141,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.POLYACRYLIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "POLYACRYLIC ACID",
        "rr": 1.07,
        "risk_count": 33187,
        "predisposition_and_risk": 48,
        "risk_duration": 20922950,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DRESSING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DRESSING",
        "rr": 1.07,
        "risk_count": 71889,
        "predisposition_and_risk": 111,
        "risk_duration": 22396273,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUOROMETHOLONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLUOROMETHOLONE",
        "rr": 1.07,
        "risk_count": 42561,
        "predisposition_and_risk": 58,
        "risk_duration": 25300817,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ICHYTHOL_.2D_ZINC_OXIDE_.2D_TITANIUM_OXIDE_COMP.2E_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ICHYTHOL - ZINC OXIDE - TITANIUM OXIDE COMP. CD",
        "rr": 1.07,
        "risk_count": 9811,
        "predisposition_and_risk": 12,
        "risk_duration": 28300557,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INDOMETACIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INDOMETACIN",
        "rr": 1.07,
        "risk_count": 21231,
        "predisposition_and_risk": 30,
        "risk_duration": 21420826,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LAXATIVE_COMP.2E_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LAXATIVE COMP. CD",
        "rr": 1.07,
        "risk_count": 26674,
        "predisposition_and_risk": 34,
        "risk_duration": 27013789,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.METOCLOPRAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METOCLOPRAMIDE",
        "rr": 1.07,
        "risk_count": 71675,
        "predisposition_and_risk": 134,
        "risk_duration": 16193228,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIRTAZAPINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MIRTAZAPINE",
        "rr": 1.07,
        "risk_count": 105653,
        "predisposition_and_risk": 201,
        "risk_duration": 18082433,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MULTIVITAMINS_FOR_OCULAR_USE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MULTIVITAMINS FOR OCULAR USE",
        "rr": 1.07,
        "risk_count": 64623,
        "predisposition_and_risk": 90,
        "risk_duration": 24772250,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.NIRVAXAL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NIRVAXAL CD",
        "rr": 1.06,
        "risk_count": 15573,
        "predisposition_and_risk": 21,
        "risk_duration": 22099320,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SALICYLIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.06,
        "risk_count": 26863,
        "predisposition_and_risk": 38,
        "risk_duration": 21070585,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SENNOSIDES_A.2BB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.06,
        "risk_count": 24627,
        "predisposition_and_risk": 34,
        "risk_duration": 21676885,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TOLNAFTATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.06,
        "risk_count": 32306,
        "predisposition_and_risk": 42,
        "risk_duration": 26164404,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CASTOR_OIL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CASTOR OIL",
        "rr": 1.06,
        "risk_count": 15434,
        "predisposition_and_risk": 19,
        "risk_duration": 27820613,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EYE_CARE_WIPES",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EYE CARE WIPES",
        "rr": 1.06,
        "risk_count": 15123,
        "predisposition_and_risk": 20,
        "risk_duration": 22568239,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLEXITOL_HEEL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FLEXITOL HEEL",
        "rr": 1.06,
        "risk_count": 22891,
        "predisposition_and_risk": 29,
        "risk_duration": 26950324,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLYCERYL_TRINITRATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLYCERYL TRINITRATE",
        "rr": 1.06,
        "risk_count": 28778,
        "predisposition_and_risk": 40,
        "risk_duration": 21445683,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INDACATEROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INDACATEROL",
        "rr": 1.06,
        "risk_count": 17183,
        "predisposition_and_risk": 21,
        "risk_duration": 28005651,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LIQUID_PARAFFIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LIQUID PARAFFIN",
        "rr": 1.06,
        "risk_count": 47772,
        "predisposition_and_risk": 73,
        "risk_duration": 19540909,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LITHIUM",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LITHIUM",
        "rr": 1.06,
        "risk_count": 42573,
        "predisposition_and_risk": 60,
        "risk_duration": 24141407,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MAALOX_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MAALOX CD",
        "rr": 1.06,
        "risk_count": 36340,
        "predisposition_and_risk": 54,
        "risk_duration": 20094688,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.MELATONIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MELATONIN",
        "rr": 1.06,
        "risk_count": 18014,
        "predisposition_and_risk": 24,
        "risk_duration": 22419980,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METFORMIN_AND_EMPAGLIFLOZIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METFORMIN AND EMPAGLIFLOZIN",
        "rr": 1.06,
        "risk_count": 22420,
        "predisposition_and_risk": 28,
        "risk_duration": 27354276,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALENDRONIC_ACID.2C_AND_COLECALCIFEROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ALENDRONIC ACID, AND COLECALCIFEROL",
        "rr": 1.05,
        "risk_count": 107000,
        "predisposition_and_risk": 180,
        "risk_duration": 20091584,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ANASTROZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ANASTROZOLE",
        "rr": 1.05,
        "risk_count": 62389,
        "predisposition_and_risk": 90,
        "risk_duration": 23429844,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.APREPITANT",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "APREPITANT",
        "rr": 1.05,
        "risk_count": 12953,
        "predisposition_and_risk": 17,
        "risk_duration": 22628345,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.NITROFURANTOIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NITROFURANTOIN",
        "rr": 1.05,
        "risk_count": 112315,
        "predisposition_and_risk": 222,
        "risk_duration": 17119988,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PAPAVERINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PAPAVERINE",
        "rr": 1.05,
        "risk_count": 44417,
        "predisposition_and_risk": 70,
        "risk_duration": 18839739,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PHENAZOPYRIDINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PHENAZOPYRIDINE",
        "rr": 1.05,
        "risk_count": 43939,
        "predisposition_and_risk": 66,
        "risk_duration": 19704915,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PNEUMOCOCCUS.2C_PURIFIED_POLYSACHARIDES_ANTIGEN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PNEUMOCOCCUS, PURIFIED POLYSACHARIDES ANTIGEN",
        "rr": 1.05,
        "risk_count": 52467,
        "predisposition_and_risk": 79,
        "risk_duration": 19685137,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PREDNISOLONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PREDNISOLONE",
        "rr": 1.05,
        "risk_count": 58049,
        "predisposition_and_risk": 80,
        "risk_duration": 24586849,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SODIUM_BICARBONATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.05,
        "risk_count": 19456,
        "predisposition_and_risk": 26,
        "risk_duration": 22164721,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.WATER_FOR_IRRIGATION",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.05,
        "risk_count": 59775,
        "predisposition_and_risk": 95,
        "risk_duration": 18645061,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.COMPRESSION_STOCKING",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "COMPRESSION STOCKING",
        "rr": 1.05,
        "risk_count": 32798,
        "predisposition_and_risk": 47,
        "risk_duration": 20632028,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIPROSALIC_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DIPROSALIC CD",
        "rr": 1.05,
        "risk_count": 50502,
        "predisposition_and_risk": 71,
        "risk_duration": 23949722,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LAMOTRIGINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LAMOTRIGINE",
        "rr": 1.05,
        "risk_count": 65098,
        "predisposition_and_risk": 113,
        "risk_duration": 17043127,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MYCOPHENOLIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MYCOPHENOLIC ACID",
        "rr": 1.05,
        "risk_count": 46532,
        "predisposition_and_risk": 65,
        "risk_duration": 24207027,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ROPINIROLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ROPINIROLE",
        "rr": 1.04,
        "risk_count": 24690,
        "predisposition_and_risk": 30,
        "risk_duration": 27560174,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SALMETEROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.04,
        "risk_count": 27887,
        "predisposition_and_risk": 35,
        "risk_duration": 26768105,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SAXAGLIPTIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.04,
        "risk_count": 13900,
        "predisposition_and_risk": 18,
        "risk_duration": 22714041,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SILVER_SULFADIAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.04,
        "risk_count": 42286,
        "predisposition_and_risk": 63,
        "risk_duration": 19752269,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SILVER_SULFADIAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.04,
        "risk_count": 68392,
        "predisposition_and_risk": 101,
        "risk_duration": 22603944,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SOFFODEX_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.04,
        "risk_count": 18210,
        "predisposition_and_risk": 25,
        "risk_duration": 21411247,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TUSSOPHEDRIN_NEW_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.04,
        "risk_count": 16439,
        "predisposition_and_risk": 22,
        "risk_duration": 21899635,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.WATER_FOR_INJECTION",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.04,
        "risk_count": 12459,
        "predisposition_and_risk": 16,
        "risk_duration": 22750587,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BRONCHOLATE_FORTE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BRONCHOLATE FORTE CD",
        "rr": 1.04,
        "risk_count": 41609,
        "predisposition_and_risk": 56,
        "risk_duration": 24970241,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CARBOSYLANE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CARBOSYLANE CD",
        "rr": 1.04,
        "risk_count": 23451,
        "predisposition_and_risk": 29,
        "risk_duration": 27067024,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DABIGATRAN_ETEXILATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DABIGATRAN ETEXILATE",
        "rr": 1.04,
        "risk_count": 57414,
        "predisposition_and_risk": 83,
        "risk_duration": 20343518,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DAPAGLIFLOZIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DAPAGLIFLOZIN",
        "rr": 1.04,
        "risk_count": 51748,
        "predisposition_and_risk": 78,
        "risk_duration": 19396268,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DEXPANTHENOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXPANTHENOL",
        "rr": 1.04,
        "risk_count": 20192,
        "predisposition_and_risk": 27,
        "risk_duration": 21848018,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXPANTHENOL.2DSODIUM_HYALURONATE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DEXPANTHENOL-SODIUM HYALURONATE CD",
        "rr": 1.04,
        "risk_count": 21360,
        "predisposition_and_risk": 26,
        "risk_duration": 27531156,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIMETINDENE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DIMETINDENE",
        "rr": 1.04,
        "risk_count": 66797,
        "predisposition_and_risk": 102,
        "risk_duration": 21931591,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INDACATEROL_AND_GLYCOPYRRONIUM_BROMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INDACATEROL AND GLYCOPYRRONIUM BROMIDE",
        "rr": 1.04,
        "risk_count": 17721,
        "predisposition_and_risk": 23,
        "risk_duration": 22511223,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KETOCONAZOLE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "KETOCONAZOLE",
        "rr": 1.04,
        "risk_count": 41947,
        "predisposition_and_risk": 57,
        "risk_duration": 24545335,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METOLAZONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METOLAZONE",
        "rr": 1.04,
        "risk_count": 33611,
        "predisposition_and_risk": 42,
        "risk_duration": 26792984,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PHENOBARBITAL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PHENOBARBITAL",
        "rr": 1.03,
        "risk_count": 33952,
        "predisposition_and_risk": 44,
        "risk_duration": 25598857,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SACCHARIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.03,
        "risk_count": 58678,
        "predisposition_and_risk": 81,
        "risk_duration": 23972563,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SELEGILINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.03,
        "risk_count": 19262,
        "predisposition_and_risk": 25,
        "risk_duration": 22378671,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TOPISALEN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.03,
        "risk_count": 25430,
        "predisposition_and_risk": 35,
        "risk_duration": 21158872,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRIAMCINOLONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.03,
        "risk_count": 65576,
        "predisposition_and_risk": 98,
        "risk_duration": 22134592,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DOMPERIDONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOMPERIDONE",
        "rr": 1.03,
        "risk_count": 78075,
        "predisposition_and_risk": 116,
        "risk_duration": 22270690,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ELBOW_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ELBOW BRACE",
        "rr": 1.03,
        "risk_count": 9297,
        "predisposition_and_risk": 12,
        "risk_duration": 22490087,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GLUCERNA_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLUCERNA CD",
        "rr": 1.03,
        "risk_count": 17715,
        "predisposition_and_risk": 23,
        "risk_duration": 22441278,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLYCERIN.2DSORBITOL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "GLYCERIN-SORBITOL CD",
        "rr": 1.03,
        "risk_count": 21451,
        "predisposition_and_risk": 26,
        "risk_duration": 27410375,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INDACATEROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INDACATEROL",
        "rr": 1.03,
        "risk_count": 31052,
        "predisposition_and_risk": 42,
        "risk_duration": 21488876,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PYRIDOSTIGMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "PYRIDOSTIGMINE",
        "rr": 1.02,
        "risk_count": 11156,
        "predisposition_and_risk": 14,
        "risk_duration": 22844694,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SERENOA_REPENS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.02,
        "risk_count": 56965,
        "predisposition_and_risk": 84,
        "risk_duration": 19573700,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.UBIQUINONE_10",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.02,
        "risk_count": 57785,
        "predisposition_and_risk": 87,
        "risk_duration": 19039587,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BALNEUM_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "BALNEUM CD",
        "rr": 1.02,
        "risk_count": 11771,
        "predisposition_and_risk": 15,
        "risk_duration": 22638842,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CINNARIZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CINNARIZINE",
        "rr": 1.02,
        "risk_count": 57727,
        "predisposition_and_risk": 88,
        "risk_duration": 18929046,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLOTRIMAZOLE_.2D_ALOE_VERA_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLOTRIMAZOLE - ALOE VERA CD",
        "rr": 1.02,
        "risk_count": 39115,
        "predisposition_and_risk": 51,
        "risk_duration": 25182032,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EMPAGLIFLOZIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "EMPAGLIFLOZIN",
        "rr": 1.02,
        "risk_count": 47983,
        "predisposition_and_risk": 61,
        "risk_duration": 25739408,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ENALAPRIL_.2D_HYDROCHLORTHIAZIDE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENALAPRIL - HYDROCHLORTHIAZIDE CD",
        "rr": 1.02,
        "risk_count": 10228,
        "predisposition_and_risk": 12,
        "risk_duration": 28100849,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULINS_SYRINGE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULINS SYRINGE",
        "rr": 1.02,
        "risk_count": 67529,
        "predisposition_and_risk": 95,
        "risk_duration": 23302412,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEVODOPA_AND_DECARBOXYLASE_INHIBITOR",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LEVODOPA AND DECARBOXYLASE INHIBITOR",
        "rr": 1.02,
        "risk_count": 78237,
        "predisposition_and_risk": 105,
        "risk_duration": 24393845,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LEVOMEPROMAZINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "LEVOMEPROMAZINE",
        "rr": 1.02,
        "risk_count": 23189,
        "predisposition_and_risk": 29,
        "risk_duration": 26152979,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ADALIMUMAB",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ADALIMUMAB",
        "rr": 1.01,
        "risk_count": 21611,
        "predisposition_and_risk": 26,
        "risk_duration": 26925807,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALFACALCIDOL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ALFACALCIDOL",
        "rr": 1.01,
        "risk_count": 125083,
        "predisposition_and_risk": 241,
        "risk_duration": 16923699,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID.2DROSE_HIPS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ASCORBIC ACID-ROSE HIPS CD",
        "rr": 1.01,
        "risk_count": 51051,
        "predisposition_and_risk": 69,
        "risk_duration": 24063422,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.OXOLAMINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "OXOLAMINE",
        "rr": 1.01,
        "risk_count": 49578,
        "predisposition_and_risk": 67,
        "risk_duration": 24063351,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2D_BRINZOLAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.01,
        "risk_count": 18139,
        "predisposition_and_risk": 21,
        "risk_duration": 28080314,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.WHITE_SOFT_PARAFFIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.01,
        "risk_count": 35703,
        "predisposition_and_risk": 50,
        "risk_duration": 20350836,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ZINC_SULFATE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1.01,
        "risk_count": 38743,
        "predisposition_and_risk": 49,
        "risk_duration": 25836522,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CANDESARTAN_.2D_HYDROCHLOROTHIAZIDE_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CANDESARTAN - HYDROCHLOROTHIAZIDE CD",
        "rr": 1.01,
        "risk_count": 67057,
        "predisposition_and_risk": 104,
        "risk_duration": 18404853,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DAPAGLIFLOZIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DAPAGLIFLOZIN",
        "rr": 1.01,
        "risk_count": 55691,
        "predisposition_and_risk": 73,
        "risk_duration": 24712294,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.INSULIN_SYRINGE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "INSULIN SYRINGE",
        "rr": 1.01,
        "risk_count": 22850,
        "predisposition_and_risk": 30,
        "risk_duration": 21667862,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METOCLOPRAMIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "METOCLOPRAMIDE",
        "rr": 1.01,
        "risk_count": 109518,
        "predisposition_and_risk": 223,
        "risk_duration": 15937672,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ANKLE_BRACE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ANKLE BRACE",
        "rr": 1,
        "risk_count": 30474,
        "predisposition_and_risk": 38,
        "risk_duration": 25935099,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ANTITHYROID_PREPERATIONS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ANTITHYROID PREPERATIONS",
        "rr": 1,
        "risk_count": 16508,
        "predisposition_and_risk": 21,
        "risk_duration": 22226863,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TEEJEL_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1,
        "risk_count": 13773,
        "predisposition_and_risk": 16,
        "risk_duration": 27763835,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.UBIQUINONE_10",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1,
        "risk_count": 89851,
        "predisposition_and_risk": 131,
        "risk_duration": 22117407,
        "predisposition_and_risk_duration": 32216,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ULTRALAN_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "NA",
        "rr": 1,
        "risk_count": 10406,
        "predisposition_and_risk": 13,
        "risk_duration": 22667566,
        "predisposition_and_risk_duration": 28218,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHLORHEXIDINE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CHLORHEXIDINE",
        "rr": 1,
        "risk_count": 62637,
        "predisposition_and_risk": 103,
        "risk_duration": 17180109,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CLINDAMYCIN",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "CLINDAMYCIN",
        "rr": 1,
        "risk_count": 60435,
        "predisposition_and_risk": 89,
        "risk_duration": 21943226,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIABETES_LANCETS",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DIABETES LANCETS",
        "rr": 1,
        "risk_count": 83839,
        "predisposition_and_risk": 128,
        "risk_duration": 21108564,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOMPERIDONE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DOMPERIDONE",
        "rr": 1,
        "risk_count": 42273,
        "predisposition_and_risk": 60,
        "risk_duration": 19948008,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DURATEARS_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "DURATEARS CD",
        "rr": 1,
        "risk_count": 33101,
        "predisposition_and_risk": 40,
        "risk_duration": 26681786,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ENCYPALMED_CD",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "ENCYPALMED CD",
        "rr": 1,
        "risk_count": 60955,
        "predisposition_and_risk": 95,
        "risk_duration": 18109928,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FUSIDIC_ACID",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "FUSIDIC ACID",
        "rr": 1,
        "risk_count": 72394,
        "predisposition_and_risk": 125,
        "risk_duration": 16360514,
        "predisposition_and_risk_duration": 28218,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROGEN_PEROXIDE",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "HYDROGEN PEROXIDE",
        "rr": 1,
        "risk_count": 41179,
        "predisposition_and_risk": 53,
        "risk_duration": 25067767,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEGESTROL",
        "predisposition": "cohort.5Fc.5F4e119a7b3d6488e8bfae3b8a184279f2",
        "risk": "MEGESTROL",
        "rr": 1,
        "risk_count": 10528,
        "predisposition_and_risk": 12,
        "risk_duration": 28265630,
        "predisposition_and_risk_duration": 32216,
        "type": "Med"
      }
    ],
    "figures": null,
    "messageType": "chronicDiseaseCohorts.report",
    "requestId": "71b41a4d-59f4-497b-978b-11277ad123dc",
    "cohortId": "c_4e119a7b3d6488e8bfae3b8a184279f2"
  },
  "id": "71b41a4d-59f4-497b-978b-11277ad123dc"
}